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ABSTRACT 
There is an escalating demand in the area of cancer prevention and control for the 
development of novel agents and molecular targets that have potential to reduce the 
incidence of cancer.  In this study, the JB6 mouse epidermal cell-culture based 
transformation model was used in efforts to identify novel chemopreventive agents and 
targets.  The nucleoside transport inhibitor dipyridamole (DPM) showed potent 
chemopreventive activity against JB6 P+ cells (tumor promotion sensitive).  To probe the 
effects of DPM structural features on its antitumor promotion activity, the soft-agar 
colony forming efficiency assay was used to screen an in-house library of structurally 
varied novel DPM analogues.  From this screening, Compound 145 was found to be 
more 30 times more potent than DPM (145, IC50 = 0.12 µM; DPM, IC50 = 3.07 µM).  
Structure-activity relationships have been defined and will aid in the next phase of 
chemopreventive drug design.  In regards to the antitumor promotion mechanism of 
DPM, a series of previously collected data are presented that support the novel hypothesis 
that nucleoside transporters may be potential chemoprevention targets involved in the 
antitumor promotion activity of DPM and analogues.  Signaling pathways are pivotal in 
tumor promotion processes and were therefore tested for in the chemopreventive 
mechanism of DPM.  In a previous study, the known chemoprevention target, AP-1, was 
studied for involvement in the antitumor promotion activity of DPM.  Using a new AP-1-
SEAP JB6 P+ reporter cell line, DPM was shown to inhibit TPA-induced AP-1 
transactivation.  Inhibition of AP-1 transactivation suggests the involvement of mitogen-
activated protein kinase (MAPK) signaling pathways which are upstream effectors of 
AP-1 transactivation, and so the involvement of MAPKs was assessed in this study.  
DPM was shown to inhibit p38 MAPK activation in a dose-dependent manner, which 
suggests that this inhibition is a potential mechanism behind the chemopreventive activity 
of DPM.   
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CHAPTER 1:  RESEARCH OBJECTIVES 
Nucleosides have been implicated as contributory agents to the processes of 
carcinogenesis.  This concept was tested in a series of preliminary work, before this 
dissertation work began, and the results supported the postulate (summarized in Chapter 
3).  Using the JB6 chemoprevention model system, these preliminary studies showed that 
exogenous nucleosides reversed the chemopreventive effects of dehydroepiandrosterone 
(DHEA).  Nucleosides require specialized transporters, namely nucleoside transporters, 
to permeate the plasma membrane and enter cells.  To further investigate the carcinogenic 
potential of nucleosides, nucleoside transport inhibitors were added to the JB6 model 
system and were found to counteract the inhibitory effects of nucleosides as well as 
inhibit tumor promotion themselves with better potency than DHEA.    
 
Subsequent investigations of nucleoside transport inhibitors as chemopreventive 
agents found that dipyridamole (DPM), a known clinically used nucleoside transport 
inhibitor, showed better antitumor promotion effects than DHEA.  Concurrently, another 
unrelated project designed to screen a library of dipyridamole analogues for inhibition of 
equilibrative nucleoside transporters afforded a novel series of DPM analogues, which 
guided the conception of the following research objectives of this dissertation.   
 
The research presented in this dissertation revolves around structure-activity 
relationship (SAR) and mechanistic studies of a series of 64 structurally varied DPM 
analogues.  The pursuit of the objectives of this work has been described in two chapters.  
Chapter 4 addresses the screening and structural insights into the chemopreventive 
potential of DPM analogues.  These studies encompass the following aims: 
 
•  To determine the antitumor promotion activity of these DPM analogues. 
  
• To quantify the relative activities by determining the IC50 values of selected 
analogues. 
 
• To use the IC50 activity data to probe structural trends in the activity to 
develop an SAR model for further drug design and optimization efforts. 
 
• To choose potent compounds for future mechanistic studies. 
 
Chapter 5 presents insights into the mechanism(s) involved in the antitumor 
promotion activity of DPM and the selected analogues. The aim of this study was to 
determine if mitogen-activated protein (MAP) kinases are involved in the antitumor 
promotion activities of DPM and analogues.  Chapters 2 and 3 provide introductory 
materials relevant to the scope of this dissertation and preliminary data used as the basis 
of this dissertation work, respectively.  
2 
CHAPTER 2:  INTRODUCTION 
The Burden of Cancer 
There is much effort across the globe to minimize the burden of cancer.  To 
present a glimpse of the cancer epidemic, here are a few facts and statistics reported by 
the American Cancer Society (ACS) about cancer in 2007 (1) . 
 
• More deaths are attributed to cancer than to AIDS, tuberculosis, and malaria 
combined. 
 
• Only outranked by heart disease, cancer is the second leading cause of death 
in the USA and other economically developed countries, causing nearly 
600,000 deaths per year. 
 
• It has been predicted that by the year 2050, the global burden of cancer will 
reach 27 million new cancer cases and 17.5 million deaths simply due to 
increasing life expectancy and overall size of the population. 
 
• The estimated overall financial cost of cancer is $200 billion dollars each 
year. 
Cancer Treatments 
One of the oldest records of cancer was found in Egypt and dates to around 1600 
B.C.  The breast tumors or ulcers that were described in this writing were treated by 
cauterization, an antiquated method that used fire to burn and destroy abnormal tissues 
(2).  Since then, cancer has become a world-wide epidemic with disheartening mortality 
statistics as presented above.  Today, cancer treatment has tremendously advanced 
because of a better understanding of this disease.  Often, multiple treatment approaches 
are used in each case depending on the prognosis, which usually include surgery, 
radiotherapy, and/or chemotherapy (1).  Even with the advances in cancer treatment 
methodologies, we are still faced with the grim statistics mentioned above. There is 
therefore an urgent need to present alternatives methods of approaching and attacking 
cancer, such as chemoprevention.  
Chemoprevention 
 The concept of chemoprevention emerged in the late1960’s.  At the time, Dr. Lee 
Wattenburg found that various chemicals were able to inhibit carcinogenesis by a 
mechanism he termed chemoprophylaxis (3).  The modern term, chemoprevention was 
coined by Michael Sporn in 1976 (4). Potential chemopreventive agents currently under 
investigation are diverse in chemical structure and physiologic effects.  Many of the 
agents that are well documented and tested have been identified from epidemiologic 
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evidence regarding the dietary and health benefits of fruits and vegetables, and other diet-
derived chemicals which include vitamins and minerals, and compounds isolated from 
teas, soybeans, broccoli, potatoes, grapes, ginger, rice, and some herbs and spices (Figure 
2.1) (5,6).  Even a few agents currently used as cancer chemotherapeutics (i.e. tamoxifen, 
finasteride) have shown chemoprevention potential in the clinical setting (Figure 2.2) 
(7,8).  
 
The cancer statistics presented at the beginning of this chapter represent the 
disconnect between the advances in cancer treatment and the resulting outcomes. Cancer 
chemotherapy involves the use of pharmaceutical drugs in efforts to remove or alleviate 
the symptoms, or to achieve a cure in by killing cancer cells throughout the body.    
Despite the benefits of chemotherapy, these treatments are often ineffective with severe 
side effects (9).   Chemoprevention offers another method to approach the attack on 
cancer.  This preventive method targets individuals who have recovered from cancer and 
may be at higher-risk for secondary cancer (10).  In addition, chemoprevention may 
benefit individuals who are otherwise healthy but have hereditary factors placing them at 
risk for developing cancer (11).  Identification of high-risk individuals may be a 
challenging endeavor but available diagnostic methods, including genetic screening, are 
helpful tools (10). 
 
Current cancer chemoprevention studies rely on the knowledge of how cancer 
begins and how it progresses (carcinogenesis) in order to design therapies to target these 
processes.  A great deal has been learned about cancer since 1946, when nitrogen 
mustards, chemical warfare agents, were observed to have therapeutic potential in 
treatment of cancer, specifically lymphomas (12).  Since then, many research efforts have 
focused on carcinogenesis and, the cellular processes involved in cancer development.  
Various models and theories regarding the causes and progression of cancer were 
presented in the 1950’s with some attributing cancer to age, and some to time and 
frequency of carcinogen exposure (13).  In the early 1970’s, the malignant phenotype (or 
manifestation of cancer) was attributed to mutations in DNA (14).  It is now clear that 
cancer is a multistage and often multifactorial process that begins with DNA mutation 
within one cell.  It is now accepted that this mutation begins the multistage process of 
carcinogenesis, which is denoted by three distinguishable steps:  initiation, promotion, 
and progression.  
Carcinogenesis 
Carcinogenesis is generally accepted as a multistep process.  The first stage, 
initiation, is a rapid (1-2 days), high frequency, and irreversible process which involves 
the induction of a gene mutation as the result of the uptake of or exposure to a 
carcinogenic agent.  In contrast to initiation, promotion is a relatively lengthy ( > 10 
years), low frequency, reversible process that requires sustained chronic exposure to  
4 
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Figure 2.1.  Structures of chemopreventive phytochemicals and their dietary sources. 
 
 
 
 
 
 
 
 
 
 
 
                    
 
                                               
 
 
 
Figure 2.2.  Structures of chemotherapeutic agents used in chemoprevention. 
Raloxifen Finasteride 
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tumor promoter(s), which supports the conversion from the initiated cell to a 
preneoplastic cell.   
 
 During the promotion phase, actively proliferating preneoplastic (precancerous) 
cells begin to accumulate.  In the case of benign preneoplastic growths, these are the end 
point of tumor promotion. In the final stage of neoplastic transformation, progression, 
benign tumors become malignant (cancerous) with invasive and metastatic potential 
(5,15).  Although each stage of carcinogenesis can potentially be inhibited, the promotion 
stage has the most potential to be reversed because of its extensive length (16).   
 
Chemoprevention is defined as the inhibition, arrest, or reversal of carcinogenesis 
by pharmacologic intervention with synthetic or naturally occurring chemicals that 
protect against the establishment of cancer or neoplastic transformation (5,8,17).  Several 
models have been used to understand the molecular mechanisms involved in 
carcinogenesis and serve as tools to analyze and design chemopreventive agents.  Two of 
these models are discussed in the next section. 
Models of Carcinogenesis 
Mouse skin carcinogenesis model 
The mouse skin carcinogenesis model is a well-characterized experimental model 
that has determined the potential roles of several genes in tumorigenesis.  The study of 
the mechanisms involved in the activation of these genes during promotion has unveiled 
a series of signaling pathways as valid targets for chemoprevention.   
 
In the mouse skin carcinogenesis model, skin tumors are induced in mice by a 
single application of a mutagen (initiation) followed by repeated application of a 
noncarcinogenic tumor promoter.  This is a model of carcinogenesis because it goes 
through the initiation, promotion, and progression phases mentioned previously.   
Initiation, which is induced by a single topical application of a subthreshold dose of a 
carcinogen, such as 7,12-dimethyl-benzanthracene (DMBA), results in irreversible DNA 
damage.  Promotion consists of repeated application of a noncarcinogenic agent, most 
commonly phorbol esters represented by 12-O-tetradecanoyl-phorbol-13-acetate (TPA), a 
potent skin tumor promoter (18).  TPA induces biochemical processes that facilitate the 
selective clonal expansion of initiated cells giving rise to numerous benign tumors 
(papillomas).  Progression, the final stage, is a spontaneous process characterized by high 
levels of genetic instability (19).  This in vivo model is important in that the data obtained 
are relevant to the whole organism.  However, in vitro models are easier to manipulate 
and more efficient in terms of cost and time. 
The JB6 model 
The mouse epidermal JB6 model is one such in vitro model designed to further 
the understanding of molecular mechanisms involved in the promotion of neoplastic 
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transformation.   Because these are epithelial cells, it is a relevant model to most human 
cancers, which have predominantly epithelial origins, particularly in skin carcinogenesis.  
The JB6 model consists of clonal genetic variants of mouse epidermal cells derived from 
BALB/c mice. In this model system, the JB6 P+ cells are promotion-sensitive.  These 
cells are “sensitive” in that they respond irreversibly to tumor promoters with subsequent 
colony growth in anchorage-independent conditions and tumorigenicity in nude mice.   
JB6 P- cells are resistant to these promotion effects (20).  Epidermal growth factor (EGF) 
and tumor necrosis factor alpha (TNF-α) are also inducers of anchorage independent 
transformation in this model (21-23). From studies using the JB6 in vitro carcinogenesis 
model, a few molecular events have been implicated in tumor promotion, and have 
proved to be predictive of tumorigenic phenotypes in vivo (24). 
Tumor Promotion with TPA:  Mechanisms Involved 
TPA, one of the most potent tumor promoters in the JB6 model, is not a genotoxic 
agent.  However,  it does induce transient changes in gene expression via signal 
transduction pathways (25-28).  This results in pleiotropic effects ranging from changes 
in cellular morphology to alterations in cell cycle and apoptosis (28). Epidermal growth 
factor (EFG) receptor (EGFR) activation is a mediator of TPA-induced signal 
transduction and transformation (Figure 2.3)  (29).  EGFR kinase inhibitors suppress 
TPA-induced phosphorylation of Erks, AP-1 transactivation, and cell transformation.  
TPA-induced phosphorylation of Erks and AP-1 DNA binding is inhibited in EGFR 
knockout cells (EGFR -/-).  In studies with EGF-induced transformation, inhibitors of p38 
and the expression of a p38 dominant negative mutant both inhibit EGF-induced cell 
transformation (30).  This adds to the understanding of mitogen activated protein kinases 
(MAPKs) in tumor-promoter induced transformation. 
 
Protein kinase C (PKC) is an intracellular receptor for TPA and is activated upon 
TPA binding (Figure 2.3) (31,32).  Because of the interaction of TPA with PKC, the 
PKC/MAP kinase/AP-1 pathway has been implicated in TPA-induced tumor promotion 
(33-36). This is supported by the observation that activation of PKC results in rapid 
activation of Erks (35,37).  However, in PKC-depleted mice, TPA is still able to 
transactivate AP-1. Several studies show TPA-induced PKC activation is a transient 
process and that continuous exposure to TPA actually downregulates PCK activity (38-
40).  In vivo, PKCα had no role in TPA-induced promotion of skin tumors.  In addition, 
PKCδ and PKCε overexpression reduced TPA-induced papillomas (41,42).  Taken 
together, these data suggest that other mechanisms in addition to the PKC pathway are 
involved in tumor promotion, which may be due to the presence of additional TPA 
receptors (43). 
TPA-induced transformation requires AP-1 
In 1989, AP-1 was  first implicated as having a key role in tumor promotion based 
on the observation  that JB6 P+ cells but not JB6 P- cells gave a tumor promoter-induced 
AP-1 response (44).  This idea that tumor promotion required AP-1 dependent gene  
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Figure 2.3.  TPA pathways in the JB6 tumor promotion model. 
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transcription was later found to have application in in vitro and in vivo mouse models, in 
human keratinocyte progression, and in other human progression models (45-47). 
 
AP-1 is a eukaryotic transcription factor composed of various dimeric 
combinations of proteins from the jun and fos oncogene families (Figure 2.4) (48,49).  
The activated dimers bind to specific transactivation promoter regions or TPA response 
elements (TREs) on DNA to induce transcription of genes involved in cell proliferation, 
differentiation, tumor promotion, and apoptosis (programmed cell death) (50).  Elk-1, a 
transcription factor that binds to the serum-response element (SRE), mediates activation 
of c-fos transcription (Figure 2.4) (51,52).   
 
AP-1 shows progressive activation in preneoplastic-to-neoplastic transformation 
and is critical in tumor promotion, progression, and metastasis (33,53,54).  A dominant-
negative mutant form of the c-Jun protein, TAM67, along with other inhibitors of AP-1 
have been used to show that AP-1 activation is required for tumor promotion and 
progression (33,55-57).   
MAPKs in AP-1 dependent transformation 
In JB6 P+, promotion with TPA results in high levels of AP-1 through the 
mitogen-activated protein kinase MAPK pathway (Figure 2.3 – 2.4) (45).  The MAPK 
family includes the extracellular signal-related kinase (Erk), c-Jun N-terminal kinase 
(Jnk) and p38 kinase which are vital mediators in the regulation of cellular proliferation, 
malignant transformation, inflammation, and apoptosis (Figure 2.4) (58-62).   
 
The MAPK cascade is shared by more than one signaling pathway is therefore 
organized into three generic sequential steps (Figure 2.4).  MAPKs are activated by 
phosphorylation by a MAPK kinase (MAPKK), which is in turn phosphorylated by a 
MAPKK kinase (MAPKKK).  Activation of MAPKKKs generally results from ligand-
receptor interactions that trigger activation and recruitment of RAS (a GTP binding 
protein), GRB2 (an adaptor molecule) and SOS (a guanine nucleotide exchange factor) 
which signals the intracellular MAPK cascade (63).  
 
Low levels of the MAPKs, Erk1 and Erk2, contribute to the tumor-promotion 
resistant phenotype in JB6 cells (64).  JB6 P- cells stably transfected with Erk2 become 
sensitive to tumor promoter-induced AP-1 activation and neoplastic transformation, while 
inhibition of Erk2 converts JB6 P+ to the resistant phenotype (64,65).  The conclusion is 
that Erk1 and Erk2 are required for tumor promoter induced AP-1 activation and for 
transformation in the JB6 model.  TPA-induced transformation does not require Jnk 
activation.  This was determined by the observation that JB6 cells expressing a dominant 
negative Jnk1 mutant are still susceptible to TPA-induced transformation (66). 
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Chemoprevention Targets 
 Signal transduction pathways appear to be good targets for chemoprevention in 
that they influence the regulation of diverse cellular pathways, particularly those involved 
in tumor promotion.  It is clear that MAPKs and AP-1 are important in tumor promoter 
induced transformation, making them valid targets for chemoprevention.  Many of the 
identified chemopreventive natural products target these signaling pathways (16).  Hence, 
this pathway was pursued in the dissertation studies (Chapter 5).  Nucleoside transporters, 
a novel potential target for chemoprevention, were also investigated (explained in 
Chapter 3). Nucleoside transporters are introduced in the next section. 
Introduction to Nucleoside Transporters 
 Nucleoside transporters (NTs) are integral membrane glycoproteins responsible 
for the cellular uptake of physiologic nucleosides and nucleobases.  In addition, 
nucleoside transporters are carriers for nucleoside analogue drugs used in the treatment of 
cancer and viral infections.  Because nucleoside transporters are the gateway into cells for 
these drugs, they play key roles in the physiologic responses to, and therapeutic 
effectiveness of natural and synthetic nucleosides. 
Nucleosides 
Nucleosides are the precursors to nucleotides and consist of a purine or 
pyrimidine nitrogenous base linked to a pentose sugar (usually ribose or deoxyribose) by 
an N-glycosidic linkage.  Nucleotides are the subunits of the nucleic acids, RNA and 
DNA.  The nucleoside units of RNA are adenosine, guanosine, cytidine, and uridine 
(Figure 2.5), while those of DNA are deoxyadenosine, deoxyguanosine, deoxcytidine, 
and thymidine (Figure 2.6).  Structurally speaking, nucleotides are nucleosides with 
phosphate groups attached to the sugar moieties by an ester linkage which allows 
polymerization through repeated sugar-phosphate groups in turn forming the nucleic acid 
backbone.  The bases connected to each sugar phosphate protrude from the backbone, 
which through hydrogen bonding, help to fashion the DNA double helix.  
 
In addition to the nucleotide subunits of nucleic acids, other biologically vital 
nucleotides (e.g. ATP, cAMP) are formed from nucleosides and therefore, nucleosides 
indirectly sustain various cellular processes including energy provision, protein synthesis, 
cell replication, and signal transduction.   
 
 As mentioned above, nucleosides are the building blocks for nucleotides.  
Nucleotide biosynthesis can occur via de novo or salvage pathways based on cell type 
(67).  For instance, hepatocytes are capable of de novo purine nucleotide synthesis, while 
specialized cells including enterocytes and brain and bone marrow cells, do not have de 
novo synthesis pathways (68).  These cells depend solely on salvage mechanisms which 
recruit extracellular nucleosides for nucleotide biosynthesis (69).  In the salvage pathway,  
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extracellular nucleotide metabolites are recycled and redistributed making cellular 
reuptake mechanisms of key importance.  Because of the hydrophilic nature of 
nucleosides, their cellular uptake is dependent upon specialized carrier proteins, in this 
case, nucleoside transporters. 
Nucleoside transporters: Classifications 
There are two major classes of  structurally unrelated nucleoside transporters 
identified in mammals, the equilibrative nucleoside transporters (ENT; SLC29 family) 
and the concentrative nucleoside transporters (CNT; SLC28 family).  Differences in 
permeant selectivity, regulation, kinetics, and localization has resulted in the 
heterogeneity of mammalian nucleoside transporters (69).  The first nucleoside 
transporters extensively studied were originally classified based on their sensitivity to 
inhibition by  nitrobenzylmercaptopurine riboside (NBMPR)  giving the designations es 
(equilibrative sensitive) or ei (equilibrative insensitive) transporters (70).  Upon 
successful sequencing and cloning of the human cDNAs, these two transporters were 
designated as ENT1 and ENT2, respectively.  ENT3 and ENT4 were identified upon 
completion of the human genome project.  In addition, ENT-like proteins have been 
identified in nonmammalian organisms (i.e. prokaryotes, fish) through exhaustive 
sequence homology searches (71).   
 
Though ENTs are predominantly bidirectional transporters that function by 
facilitated diffusion, some family members are proton-dependent concentrative 
transporters (72).  The ENT subtypes are widely distributed within the human body and 
are the most studied and best characterized nucleoside transporters (73).  The CNT 
proteins are unidirectional cation symporters and are found in eukaryotes and bacteria 
(73).  There are five classifications of concentrative nucleoside transport process (cit, cif, 
cib, csg, cs).  Six functional CNT subtypes have been identified in humans.  The three 
best characterized are the Na+-dependent transporter designated as cit (CNT1), cif 
(CNT2) and cib (CNT3) (74). 
Nucleoside transporters: Homology  
Equilibrative nucleoside transporters 
Human ENT1 (hENT1) was first purified from human erythrocytes in 1988 (75). 
Approximately ten years later, it was successfully cloned from human placenta and found 
to encode a 456-residue glycoprotein.  Molecular cloning and functional characterization 
of the rat homologue (rENT1) revealed a 457-residue protein with 78% identity to 
hENT1 (76).  Cloning of a mouse homologue (mENT1.1) revealed a 460-residue protein 
79% identical to hENT1 (77).  A 458-residue splice variant of the mouse protein 
(mENT1.2) was identified and shown to be widely distributed.  This variant lacks a 
putative casein kinase II phosphorylation site, but exhibits normal transporter functions 
(77). 
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 Like hENT1, the cDNA clone encoding human ENT2 (hENT2) was also isolated 
from human placenta and identified as a 456-residue protein 46% identical to hENT1 
(78).  Cloning of the rat (rENT2) and mouse (mENT2) revealed them both to be 456-
residue proteins with 88% identity to hENT2 (76,79).   One ENT2 splice variant shows 
high sequence homology with HNP36 (326-residues), a growth factor induced delayed 
early response gene (76,78,80).  This spliced product does not have the first three 
transmembrane helices of ENT2 and is not a functional transporter (80).  Another splice 
variant is widely distributed and encodes a 301-residue protein truncated at the C-
terminus (hENT2A) and lacks transporter activity (81). 
 
 Human ENT3 (hENT3) has 475-residues and is 29% identical to hENT1.  hENT3 
has 74% sequence identity with the 475-residue mouse variant (mENT3) (72).  Human 
ENT4 (hENT4) has 530-residues and is 86% identical to its 528-residue mouse 
homologue (mENT4).  hENT4 has only 18% homology with hENT1 which represents 
some phylogenetic divergence for the hENT4 subtype (82). 
Concentrative nucleoside transporters 
 Human CNT1 (hCNT1), cloned from the kidney, is a 71 kDa protein of 650 
residues.  Human CNT2 (hCNT2) is also a 71 kDa proteins but 658 residues and 72% 
identical to hCNT1.  Rat CNT1 (rCNT1) is 83% identical to hCNT1 (83,84).  Human 
CNT3 (hCNT3), cloned from the human mammary gland, is a 691 residue protein 78% 
identical to the mouse CNT3 (mCNT3).  Human CNT3 (hCNT3) is 47 and 48% identical 
to hCNT2 and hCNT1, respectively (85). 
Nucleoside transporters: Topology/Structure 
 Equilibrative nucleoside transporters (ENT1-4) are predicted to have 11-
transmembrane spanning domains with glycosylation sites in the loop between 
transmembrane domain (TM)1 and TM2 (Figure 2.7) (69,75,86).  Glycosylation sites are 
similarly located in ENT2 and ENT3 whereas ENT4 has putative glycosylation at the C-
terminus (87).  Various structural studies have been done to better understand 
permeant/and or substrate binding to nucleoside transporters.  Chimera and mutagenesis 
studies between ENTs of various species indicate that TM1, TM2, TM4, TM5, TM8, and 
TM11 arrange to form a solvent-accessible substrate binding site (69,88-90).  This 
arrangement suggests the ENT family may have 3D structures similar to members of the 
major facilitator superfamily (i.e. bacterial lactose transporter, LacY) despite little 
sequence homology between the two families (69,88,91). 
 
 Both the ENT and CNT family proteins have a cytoplasmic N-terminus and an 
extracellular C-terminus (Figure 2.7).  A characteristic difference between h/mENT3 and 
the other ENTs is its long (51 residue) N-terminus (73).  The topology of CNT is 
believed to consist of 13 membrane spanning domains with TM7 and TM8 implicated in 
permeant selectivity.  Cation binding sites are likely located in the C-terminal region of 
the protein (92). 
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Figure 2.7.  Topographical model of ENTs and CNTs. 
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Nucleoside transporters:  Localization/Tissue distribution/Abundance  
All of the ENTs are widely distributed in mammalian tissues but each subtype has 
regions of noteworthy localization compared to other family members.  ENT1 can be 
found in erythrocytes, heart, kidney and CNS (81,93-96).  ENT2 is particularly abundant 
in skeletal muscle but is also found in brain, heart, lung, thymus, prostate and pancreas 
(80,96).  ENT3 is particularly abundant in the heart and brain while ENT4 is more 
abundant in brain and skeletal muscle. 
 
CNTs are predominantly found in highly differentiated tissues (i.e. intestine and 
kidney epithelia) (96,97).  CNT1 is found in the liver, kidney, and small intestines and 
present at low levels in other tissues (92,96).  CNT2 and CNT3 are widely distributed 
(96).  CNT1 and CNT2 are primarily localized to the apical membrane of polarized 
kidney epithelial cells while ENT1 and 2 are localized to the basolateral membrane.  This 
arrangement implies that nucleoside reabsorption in kidney is mediated by nucleoside 
transporters (69,98).  h/mENT3 is localization to mitochondria and lysosomal membranes 
(72). 
Nucleoside transporters:  Substrates/Permeants 
Nucleoside transporters are important for the provision of dietary or physiologic 
nucleosides as well as various nucleoside analogue drugs.  
Nucleosides/nucleobases 
ENT1-3 transport a broad range of purine and pyrimidine nucleosides, whereas 
ENT2-3 can also transport nucleobases (69,99).  There are variations in substrate 
affinities between ENT1-ENT3.  A deviation within this family in terms of permeant 
selectivity is presented by hENT4, which transports monoamines and other organic 
cations.  Adenosine is transported by all four ENT family members (73).  ENT4 is not 
known to transport other nucleosides besides adenosine.  CNT1 transports pyrimidine 
nucleosides and adenosine while CNT2 transports purine nucleosides and uridine 
(84,100).  CNT3 is broadly selective for purine and pyrimidine nucleosides (101).  
Nucleoside analogue drugs  
A variety of nucleoside analogs are of great therapeutic significance as antitumor, 
antiviral, and antibiotic agents (102).  Nucleoside analogue drugs are metabolized to 
activated triphosphates intracellularly and interfere with nucleic acid synthesis by 
targeting enzymes involved in nucleoside metabolism or nucleic acid synthesis, or by  
 
DNA/RNA incorporation which interferes with repair mechanisms, among others. In the 
end, the cytotoxic response to nucleoside analogue drugs is cellular apoptosis (69,103). 
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Most nucleoside analogue drugs are hydrophilic, therefore the resultant 
therapeutic response mainly depends on nucleoside transporter mediated uptake into the 
cells so that nucleoside analogue drugs can be metabolized and activated.  For this reason 
NTs have become a focal point in studies regarding the clinical efficacy of nucleoside 
analogue drugs.   
Anticancer nucleoside analogue drugs 
Some of the first chemotherapeutic agents in the treatment of cancer were 
nucleoside analogue drugs.  Cladribine and fludarabine are purine nucleoside analogues 
used mainly in treatment of hematologic malignancies. Pyrimidine nucleoside analogs 
include cytarabine, which is mainly used in the treatment of acute leukemia, and 
gemcitabine which is used to treat solid tumors and some hematologic malignancies.  
Flurouracil and capecitabine, fluorinated pyrimidine drugs, are used to treat colorectal 
and breast cancer (103). 
 
 CNT1 is a high affinity transporter for fluoropyrimidines.  Fludarabine transport 
is mediated by hENT1, hENT2, hCNT2, and hCNT3 (101,104-106).   Cladribine is a 
permeant of the same transporters as fludarabine which implies similar structural 
specificities (101,104,107-109).  Gemcitabine is a permeant for most NT subtypes, but 
particularly hENT1 and hENT2 (101,110-112).  Cytarabine is a permeant of hENT1 and 
hENT2 but not hCNT1, hCNT2, or hCNT3 (111,113).  Figure 2.8 shows various 
anticancer nucleoside analogue drugs. 
Antiviral nucleoside analogue drugs 
The first drug approved for the treatment of AIDS and HIV was the antiviral 
nucleoside analog drug, zidovudine (AZT), which inhibits reverse transcriptase (103).  
Through the enzymatic reactions of reverse transcriptase, viral RNA is transcribed into 
DNA which becomes integrated into the genome of the host and ultimately replicated.  
Other NAD reverse transcriptase inhibitors include lamivudine and tenofovir (103). 
 
h/rENT2 is the primary transport mechanism for the antiviral nucleoside analogue 
drugs 2’3’-dideoxycytidine (ddC) and 2’3’-dideoxyinosine (ddI) and 3’-azido-3’-
deoxythymidine (AZT).   On the other hand,  h/rENT1 only poorly transport ddC and ddI 
and does not transport AZT which suggests that the 3’-hydroxyl group is important in 
substrate recognition by ENT1 (114). 
Nucleoside transporters in the efficacy of nucleoside analogue drugs 
The abundance and tissue distribution of NT proteins has been connected to  
cellular specificity and sensitivity to Nucleoside analogue drugs (115).   A study 
comparing NT expression in normal and tumor tissues provided evidence that 
interindividual variations in nucleoside analogue drug response and development of 
resistance may result from the observed differences in functional expression and/or  
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Figure 2.8.  Various anticancer nucleoside analogue drugs. 
 
 
genetic polymorphisms in nucleoside transporters (74,116).  In this NT profiling, levels 
of hENT1 mRNA were lower in some tumors compared to normal tissues.  However, in 
breast, lung, stomach, and rectal cancers, hENT1 expression was higher than normal.  
Ovarian tumor showed higher hCNT1 expression compared to normal tissue samples 
while other tumors had lower hCNT1 expression.  Most of the breast, prostate, uterine, 
ovarian, and lung cancers expressed more hCNT2 mRNA than the normal tissues.  
Significant differences in NT expression between cell types within the same tissue were 
also observed (116). 
 
It is postulated that increased expression of hENT1 may confer selectivity of 
Nucleoside analogue drugs to certain malignant cells as evidenced by the association of 
increased proliferation rates to increased es-type transporter levels (117,118). This is 
supported by the observation that levels of NTs correlated to cladribine sensitivity in 
acute lymphoblastic leukemia cells in vitro (119). 
 
Resistance to Nucleoside analogue drugs may result from poor uptake due to 
inadequate transporter expression.  In the case of the pyrimidine nucleoside analogue 
drug gemcitabine, hENT1 has been shown to be the major route of uptake and deficiency 
in hENT1 has been associated with gemcitabine resistance (120).  Amongst patients with 
pancreatic adenocarcinoma, the absence of hENT1 showed a positive correlation to a 
decrease in survival time (121).    hENT1 expression has also been implicated as a 
potential mechanism of resistance to cytarabine by leukemias (122,123). 
 
19 
hENT1, hENT2 and hCNT1 levels were determined in nearly 300 gynecologic 
tumors and it was found that hCNT1 was lost in a much higher number of cases than 
hENT1 or hENT2.  NT-negative tumors were associated with poor prognosis which 
could be due to the fact that these transporters recognize fluoropyrimidines as substrates 
(124).  The identification of NT genetic polymorphisms in transporters can also aid in the 
predictive aspects of NT profiling (125). 
Physiologic roles of nucleoside transporters 
Adenosine has a broad range of important physiologic roles in the body and 
requires nucleoside transporters for cellular translocation.  Adenosine controls the supply 
and demand of energy in tissues through ATP.  Metabolic stress and cell damage trigger 
the release and accumulation of adenosine in extracellular space.  This accumulation of 
adenosine has various downstream effects some of which involve modulation of 
homeostasis.  In the cardiovascular system, adenosine protects against injury produced 
during ischemia and reperfusion (126).  Adenosine mediates cytoprotection in the central 
nervous system in response to metabolic insults such as ischemia and hypoxia (126).  
Other noted roles of adenosine include inhibition of lipolysis, regulation of the immune 
system, and involvement in sedation and vasorelaxation (102,126).  The physiologic 
effects of adenosine are mediated partly through interaction with plasma membrane 
adenosine receptors.  Four receptor types have been cloned to date (A1, A2A, A2B, and 
A3) all of which are 7 transmembrane spanning G-protein coupled receptors (127).   
 
Adenosine produced via de novo mechanisms intracellularly or salvage 
mechanisms is transported in and out of cells by nucleoside transporters distributed 
throughout the CNS (69).  Stressful conditions such as cerebral ischemia, inflammation,  
and seizure trigger cytoprotective and neuromodulatory adenosine responses (69,126).  
Studies also suggest adenosine involvement in the neuronal responses involved in 
alcoholism and drug addiction (128,129).  Cellular ethanol models of intoxication have 
shown that in response to ethanol exposure, adenosine is a common mediator in the 
resultant changes in neuronal function, signal transduction, and gene expression 
(129,130).  Adenosine has also been found to have neuromodulatory effects on sleep and 
wakefulness, and inflammatory or neuropathic pain (131,132).    
 
 Cardioprotection mediated by adenosine has been extensively studied.  The 
pharmacologic cardiovascular benefits of adenosine result from its actions as an 
antithrombotic, antiarrhythmic, and a vasodilator (133).   
Regulation of nucleoside transporter expression and consequences 
Nucleoside transporter abundance is partly dependent upon cellular proliferation 
and differentiation signals.   Various mechanisms have been proposed for the cell and 
tissue specific regulation of NT expression.  In cultured adrenal chromaffin cells, it was 
observed that TPA-induced activation of PKC resulted in a decrease in the number of 
high affinity NBMPR binding sites (i.e. hENT1) (134).  In another study, TPA-induced 
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differentiation of HL60 cells resulted in a rapid decrease in NBMPR-sensitive nucleoside 
transport via activation of PKC (135).  Another study was aimed at determining the acute 
affects of TPA-stimulation in cultured human MCF-7 and HeLa cells.  These cancer cells 
have well-characterized NT and are known to express hENT1 and hENT2 but not CNTs.  
It was shown that acute TPA stimulation results in a rapid increase in hENT1-dependent 
nucleoside uptake.  PKC δ and/or ε were found to mediate the observed acute effects.  
This study also confirmed the decrease in NBTI-sensitive transport after long-term PMA 
treatment as seen in the HL60 and chromaffin cells (136). 
 
Study of the regulation of nucleoside transport in human B-lymphocytes found 
TPA and lipopolysaccharide stimulation resulted in a decrease in equilibrative nucleoside 
transport and hENT1 mRNA levels. In contrast, these stimuli upregulated concentrative 
transport systems in the B-lymphocytes (137).  
 
Several postulates have been put forward regarding PKC regulation of NTs 
including:  PKC-induces conformational changes which may be a result of post-
translational modifications (phosphorylations) altering transport capacity and binding 
affinities.  Underlying regulatory factors in NT expression are rates of 
internalization/recycling and rates of synthesis/breakdown (136). 
 
The regulatory response of es has been shown to require nitric oxide (NO) in B 
lymphocytes (138).  Nerve growth factor stimulates adenosine transport in cultured 
bovine chromaffin cells (139).  Colony-stimulating factor 1 (CSF-1), macrophage growth 
factor, was found to stimulate es-type transport activity in mouse macrophage cells, also 
with connections to cell cycle (140).  
 
 NT expression has also been correlated with the cell-cycle.  hENT1 transporter 
expression doubles between the G1 and G2-M phases in cultured human cancer cells. 
Hydroxyurea and 5-FU (antimetabolites that inhibit de novo synthesis of DNA precursors 
or that inhibit DNA synthesis), produced an increase in hENT2 expression suggesting 
transporter synthesis and/or expression is regulated by cellular nucleotide levels (141).  
Much like the ENTs , CNT1 and CNT2 expression has similar reports of expression 
being dependent upon cell cycle, hormones, cytokines, and proliferative status (137,142-
144). 
 
Together these data suggest that rapid functional modifications of NTs in addition 
to more transient effects on NT expression are involved in NT regulation in response to 
various stimuli. Changes in expression of NTs will have an effect on intracellular drug 
bioavailability in addition to efficacy of drugs directly targeting NTs. Better 
understanding of NT regulation can help elucidate the factors involved in drug targeting 
and sensitivity, and possibly carcinogenesis.  Variations in NT regulation between cell 
types may also offer a guide in the development selectively targeted therapies (cell-type 
specific). 
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Nucleoside transporters as therapeutic targets:  Nucleoside transport inhibitors 
The classification of the family of NT transporters began based on sensitivity to 
inhibition by the nucleoside analogue nitrobenzylmercaptopurine riboside (NBMPR), the 
prototype ENT1 inhibitor. ENT1-mediated transport is strongly inhibited by NBMPR at 
subnanomolar levels (Ki = 0.4-2 nM) while ENT2 is inhibited weakly in the micromolar 
range (69).  NBMPR is a potent nucleoside transport inhibitor but its potential 
immunosuppressive and mutagenic effects have hampered its establishment as a 
clinically useful agent (145,146).  Other potent nucleoside transporter inhibitors are 
dipyridamole (pyrimidopyrimidine), draflazine and soluflazine (piperazines), and dilazep 
which are used as coronary vasodilators.  Figure 2.9 shows a few of these compounds.  A 
host of structural classes have been identified as inhibitors of nucleoside transport 
(reviewed in Buolamwini 1997 (102)). 
 
hENT1 is the pharmacologic target for the coronary vasodilators dipyridamole 
and dilazep (75).   Among the ENT1 mammalian isoforms, only rENT1 is insensitive to 
inhibition by these NT inhibitors (75,76,79).  Otherwise, the mammalian ENT1 isoforms 
are more sensitive to inhibition by NBMPR, dipyridamole, and dilazep  than the ENT2 
isoforms (75,76,79,80).  Inhibitors of the sodium dependent concentrative nucleoside 
transporters are less characterized.  The few concentrative transport inhibitors that are 
known currently are phloridzin, 5’-position modified nucleoside derivatives, 
benzimidazole ribofuranosides, and 8-position modified purine nucleoside derivatives 
(147-150). 
 
In a study to determine the effects of p38 MAP kinases on regulation of cytaribine 
(Ara-C), protein kinase inhibitors were also observed to inhibit nucleoside transport.  
Since this discovery, a range of structurally diverse serine/threonine kinase inhibitors 
have been screened and found to inhibit hENT1.  SB203580-iodo, a p38 MAPK inhibitor 
and Ro 31-6045, a PKC inhibitor analogue showed low nanomolar Kis (151,152). 
Adenosine potentiation 
Inhibition of nucleoside transporters potentiates the effects of adenosine by 
blocking its reuptake and causing its extracellular accumulation.  Dipyridamole, dilazep, 
draflazine, and lidoflazine are inhibitors of ENT1 which therefore inhibit adenosine 
reuptake.  This results in vasodilation via the interaction of adenosine with the A2 
receptors. Nucleoside transporter inhibitors have also been proposed to have potential use 
in open heart surgery to prevent ischemic damage, and in heart transplantation for 
preservation of cardiac tissues (95,153). 
 
In the CNS, extracellular accumulation of adenosine mediates neuroprotection 
(154).  The moderate nucleoside transport inhibitor propentofylline has been shown to 
increase adenosine levels and prevent ischemia-induced brain damage in rats (155,156).  
Nucleoside transport inhibitors may also potentiate the anti-inflammatory antinociceptive 
effects of adenosine.   
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Figure 2.9.  Structures of representative nucleoside transport inhibitors. 
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Antimetabolite potentiation 
Nucleoside analogue drug cancer (antimetabolite) therapies rely heavily on 
nucleoside transport for cellular uptake and clinical efficacy.  Nucleoside transporters are 
also key players in the salvage of preformed nucleosides which present a means to 
circumvent antimetabolite drug activity.  The salvage of nucleosides and nucleobases is 
enhanced in many human tumors which may allow cancer cells to overcome 
antimetabolite toxicity (157).  This results in antimetabolite resistance which is a serious 
problem in cancer chemotherapy (125,158).  Inhibition of nucleoside transport has been 
studied in preclinical and clinical models as a mechanism to modulate antimetabolite 
resistance and efficacy. 
 
ENTs are bidirectional and therefore mediate both the uptake and efflux of 
therapeutic Nucleoside analogue drugs.  Therefore, selective inhibition of ENTs is a 
promising method to enhance the efficacy of Nucleoside analogue drugs, particularly 
those taken up into cells by concentrative nucleoside transporters.  This theory has been 
tested with promising results.  Acute lymphocytic leukemia cells exposed to cladribine 
followed by treatment with NBMPR to prevent efflux shows enhanced cladribine 
cytotoxicity (159). 
 
Dipyridamole has been studied most extensively in the clinical setting with 
promising potential (discussed in more detail in a later section), however partly due to 
pharmacologic limitations, the clinical use of this agent in antimetabolite potentiation has 
been abandoned.  The search continues for more potent and clinically acceptable 
nucleoside transport inhibitors. 
Antiprotozoal 
Most pathogenic parasites lack salvage pathways of purine nucleotide 
biosynthesis and rely on uptake of nucleoside and nucleobases from the host for salvage 
synthesis.  In protozoa involved in human diseases such as sleeping sickness, 
lieshmaniasis and malaria, the equilibrative nucleoside transporters are important in the 
acquisition of salvage nucleosides.  Methods of targeting NTs in antiparasitic therapies 
aim to exploit variations in permeant selectivity between the host and parasite NTs (160).  
Possible selective toxicity towards the parasite coupled with host protection could be 
attained using host specific nucleoside transport inhibitors.  This has been demonstrated 
by using a phosphate-derivative of NBMPR to protect mice infected with Schistosoma 
mansoni from tubercidin toxicity while retaining toxicity against the parasite (161). 
The Future of Nucleoside Transport Inhibitors: A Medicinal Chemistry Perspective 
 The therapeutic use of NTIs has been unsuccessful due to poor pharmacologic 
profiles in regards to toxicity and lack of in vivo efficacy.   In the absence of any crystal 
structures of the nucleoside transporters, the development of novel inhibitors with better 
clinical profiles relies heavily on ligand-guided drug design. Studies in our research 
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group have used current nucleoside transport inhibitors (i.e. NBMPR, DPM) as structural 
scaffolds from which to extract structural activity relationships (SAR) to direct the 
synthesis of agents with better potency and ADME/TOX profiles. 
 
  Known agents are useful as molecular probes in screening for novel NTIs.  The 
fluorescent es transporter ligand, SAENTA-X8-fluorescein, has been used in the 
identification of potent NTIs from structure-guided synthesis and flow cytometric 
analysis (162-164). 
 
Other structure-based design efforts are underway in our lab to probe the NTI 
binding site(s) to enhance the specificity of NTIs.   Structural analogs of NBMPR have 
been designed and used to probe binding conformation of inhibitors and as photoaffinity 
probes to identify the amino acids involved in inhibitor binding (165,166). 
Summary of Nucleoside Transporters  
Overall, nucleoside transporters indirectly regulate a host of physiologic processes 
that require or are affected by nucleoside uptake.  They are also important in the 
pharmacologic responses to nucleoside analogue drugs.  Nucleoside transport inhibitors 
can also be used to modulate responses to nucleoside analog drugs in addition to 
physiologic nucleosides, such as adenosine.  DPM, the nucleoside transport inhibitor 
around which this dissertation is focused, is formally introduced in the next section. 
Introduction to Dipyridamole 
Dipyridamole, a pyrimidopyrimidine, inhibits both ENT1 and ENT2 transporters.  
DPM inhibits [3H] uridine uptake in PK15 hENT1 and hENT2 cells with an IC50 of 5 nM 
and 356 nM, respectively (164).  Its NT inhibitory activity has been exploited in clinical 
trials in efforts to increase cytotoxicity of the antimetabolite 5-fluorouracil (5-FU).   
Inhibition of NT by DPM showed enhance 5-FU cytotoxicity in vitro, however, this 
response was not seen in the clinical setting (167-170).  A DPM analogue, BIBW22BS, 
increased the antiproliferative effects of 5-FU in colon cancer cell lines but not in human 
tumor xenografts grown subcutaneously in nude mice.  DPM has also been shown to 
potentiate the growth inhibitory effects of the antifolate drug, methotrexate, through 
inhibition of thymidine transport in HCT116 human colon cancer cells.  Unfortunately, 
this enhanced toxicity effects normal cells as well (171,172).   
 
Dipyridamole has broad pharmacological effects such as vasodilation, anti-
inflammatory, and antioxidant effects (173).  DPM is known in the clinical setting as the 
cardiovascular agent Persantine.  In 1979, the cardiovascular response to DPM was 
attributed to the prevention of platelet aggregation via inhibition of adenosine uptake 
(174).  Extracellular adenosine comes from the breakdown of ATP by nucleases.  DPM 
blocks nucleoside transport mediated adenosine reuptake into the cells and adenosine 
levels accumulate outside the cell (175,176).  Adenosine interacts with the A2 adenosine 
receptors which stimulate adenylate cyclase resulting in increased levels of intracellular 
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cAMP.  cAMP is a potent inhibitor of platelet activation.  DPM also increases cAMP and 
cGMP by preventing breakdown by phosphodiesterase (177,178).  Prostacyclin (PGI2), a 
potent inhibitor of platelet aggregation, is stimulated by DPM through its activation of 
cAMP (179).  Combined, these actions facilitate vasodilation. 
 
Due to its vasodilatory effects, DPM is used in cardiac stress tests.  During these 
tests, DPM is administered IV and increases local adenosine.  This results in vasodilation 
of healthy arteries while blood flow in the blocked arteries remains low.  The effects of 
which are monitored by electrocardiographic or imaging techniques (180,181). 
 
Because of the antiplatelet activities of DPM, it is most commonly used as an 
antithrombotic.  Thrombosis is the formation of blot clots within blood vessels.  Platelets 
accumulated on the surfaces of diseased vessels become adhesive substrates for 
monocytes. The platelet-monocyte interaction stimulates a proinflammatory and 
prothrombotic activities, with clinical manifestations such as stroke or myocardial 
infarction (182-186).  One caveat in the clinical administration of DPM is its binding  
plasma α-acid glycoprotein and albumin which limits available free serum concentrations 
(187).  Therefore, DPM has a compromised bioavailability.   
 
The clinical agent Aggrenox is a combination of extended-release DPM and 
aspirin, which results in the additive antiplatelet actions of these two drugs. Aggrenox  is 
used to reduce the risk of a secondary stroke in patients with previous occurrence of 
stroke/transient ischemic attack (188).  In cardiovascular medicine, the introduction of 
chemopreventive drugs such as Aggrenox which inhibits platelet aggregation and others 
agents that inhibit cholesterol synthesis, and lower blood pressure, has significantly 
reduced heart disease incidence and mortalities.  Some of the agents are widely used,  
even in otherwise healthy asymptomatic patients, despite their undesirable and potentially 
serious side effects (17).   It should then only be rational to adamantly pursue the 
discovery of cancer chemopreventive agents in order to minimize the burden of cancer 
across the globe.  This dissertation work investigates the chemopreventive activity of 
DPM using structure-based and mechanistic approaches.   
 
26 
CHAPTER 3:  PRELIMINARY DATA 
Nucleosides and Nucleoside Transport Inhibitors in Carcinogenesis   
A few key pieces of evidence guided the rational basis of our interest in studying 
the roles of nucleosides and nucleoside transporters (NTs) in carcinogenesis.  Neoplastic 
(cancer) cells are quite distinguishable from their normal counterparts in that they do not 
succumb to the regulatory mechanism of growth and differentiation.  When a somatic cell 
has aged or becomes damaged, it commits suicide (apoptosis) for the sake of the integrity 
of genome.  Cancer cells are more selfish and have a more renegade agenda:  to make 
more copies of themselves.  This happens in a more rapid and uncontrolled manner than 
normal due to an acquired ability to evade the mechanisms that regulate cell proliferation 
and cell death.  Increased propogation rates then places an escalating demand on nucleic 
acid synthesis, and some cancer cells may accommodate this pressure by increasing de 
novo and/or salvage nucleotide biosynthesis.  Nucleoside transporters are essential for 
transport of the nucleosides required for nucleotide biosynthesis.  
 
We present the concept that nucleoside transporters may be a valid target in 
chemoprevention efforts.  This hypothesis has supporting evidence from other labs in 
addition to studies done by our research group which are presented in this chapter. 
Nucleosides in carcinogenesis 
Two decades ago, it was reported that increased activities of  key enzymes 
involved in both salvage and de novo nucleotide biosynthesis have positive correlations 
with neoplastic transformation and subsequent progression (157).  Other reports observed 
that supplementation with deoxyribonucleosides or ribonucleosides resulted in resistance 
to the antitumor promotion effects of DHEA and its derivative fluasterone in TPA-
induced skin tumors in mice (189,190).   Other independent research found that 
exogenous supplies of ribonucleosides were able to reverse the antitumor promotion 
effects of  DHEA in bladder cancer (191).   
Nucleoside transporters in neoplastic transformation 
From the introductory materials in Chapter 2, it is clear that NTs are important in 
cancer chemotherapy.  Stimulation of growth and cell cycle progression, which are often 
dysregulated in cancers, have been shown to affect nucleoside transport activity.  Some 
neoplastic cells are able to increase the intake of exogenous nutrients based on cell-
specific demands (192).  Higher levels of nucleoside transport (mainly hENT1) were 
observed in rat-2 v-fps transformed fibroblasts compared to the wild-type cells (193).  
Nucleoside transport in quiescent S1 macrophages is predominantly via the es transporter 
which was increased 3-fold by stimulation with CSF-1.  A progressive increase in es 
transporter expression was also observed in vivo upon administrations of granulocyte-
macrophage colony stimulating factor-1 to patients with acute myeloid leukemia (194).   
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Rapid cell division has been found to stimulate es transporters in a variety of 
hemapoietic cells and Na+-dependent transport in the liver (118,194,195).  The thymus is 
a recognized site of active T-lymphoid cell proliferation and DNA synthesis. This 
proliferative increase in NT in human thymocytes and lymphocytes has a direct 
connection to DNA synthesis.   T-acute lymphoblastic leukemia, believed to arise in the 
thymus, is characterized by high proliferation rates paralleled by a high density of 
nucleoside transport sites (196).  These facts only add to the connection between 
nucleoside transporters and transformation in particular through the demand for higher 
levels of DNA synthesis. A rapid decrease in growth and a decrease in the number of es 
transporter accompanies PMA or DMSO-induced differentiation of  HL-60 promyelotic 
leukemia cells (135).  Prolonged tamoxifen exposure resulted in the expected retardation 
in cell growth in MCF-7 cells accompanied by a decrease in the total number of 
NBMPR-binding sites.  Freshly harvested tumor tissues from human breast, colorectal, 
liver, and stomach cancer had higher numbers of NBMPR binding sites than their normal 
counterparts (197). 
 
Taken together, the above mentioned observations lead to the idea that preformed 
ribonucleosides and deoxyribonucleosides may be used in salvage pathways of cellular 
nucleic acid biosynthesis by preneoplastic or neoplastic cells for tumor promotion and 
progression.  Since nucleoside transporters are required for the cellular uptake of these 
nucleosides, they may therefore be potential chemoprevention targets.  A series of 
preliminary data was accumulated that supported this hypothesis and sparked the 
subsequent studies of this dissertation (Chapters 4 and 5).   The results of the preliminary 
studies are presented in the following sections. 
Nucleoside transport inhibitors and nucleosides in tumor promotion 
In efforts to test the hypothesis that nucleoside transport inhibitors have potential 
use in chemopreventive therapies, in vitro experiments were performed looking at effects 
of nucleoside transport inhibitors on tumor promotion.  The chemopreventive agent, 
DHEA, was used to analyze the chemopreventive potential of the studied nucleoside 
transport inhibitors. 
 
The first experiments were performed to observe the effects of exogenous 
nucleosides, and nucleoside transport inhibitors on the anti-tumor promotion activity of 
DHEA.  Based on the fact that inhibition of nucleoside transport using compounds such 
as NBMPR and DPM effectively interferes with salvage nucleotide biosynthesis, 
NBMPR and DPM were the NTIs of choice in this investigation.  
  
A summary of the results is as follows: 1) DHEA shows an anti-tumor promotion 
effect in the JB6 P+ TPA-induced tumorigenic model, 2) the addition of the 
deoxyribonucleoside cocktail had a significant antagonistic effect on the antitumor 
promotion effect of DHEA in this model, and 3) the nucleoside transport inhibitors 
NBMPR (10 μM) and dipyridamole (5 μM) reversed the antagonistic effects of the 
extracellular nucleosides, thus restoring the anti-tumor promotion activity of DHEA, with 
DPM being better than NBMPR in this regard.  The results indicate that, as is the case 
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reported in the literature for mouse skin cells, external nucleosides do negate the anti-
carcinogenesis effects of DHEA in the JB6 tumor promotion model as well, at the 
concentrations used (Figure 3.1). 
 
 Additional experiments tested the concentration-dependent effects of NTIs in 
comparison to DHEA.   Below are the resulting dose-response curves after treatment of 
JB6 P+ cells with various concentrations of the chemopreventive agent DHEA, or 
nucleoside transport inhibitors, NBMPR or dipyridamole (DPM).   The cells were 
incubated with 16 nM TPA in the presence or absence of a 50 µM deoxyribonucleoside 
cocktail (Figure 3.2). 
 
These experiments show that in the presence of the tumor promoter, TPA, the 
nucleoside transport inhibitors have antitumor activity with DPM being more potent.  In 
the presence of nucleosides, the effects of the nucleoside transport inhibitors were 
antagonized.  The reduction in antitumor promotion activity was more pronounced with 
nucleosides and nucleoside transport inhibitors than with nucleosides and DHEA.  This 
indicates that the effects of the nucleosides are possibly connected to the nucleoside 
transport activity. 
Characterization of Nucleoside Transport Phenotype in JB6 P+ Cells 
To validate using JB6 P+ cells to study the chemopreventive potential of NTIs, the 
NT phenotype was first characterized in these cells.  The functional expression of 
concentrative and equilibrative nucleoside transporters was measured by the dependence 
or independence of nucleoside transport on a sodium ion (Na+) gradient, a standard 
method in NT characterization. After determining Na+-dependent or independent 
transport, NTs are further classified as es (ENT1) or ei (ENT2) subtypes based on their 
sensitivity to NBMPR inhibition.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.  Effects of nucleosides and nucleoside transport inhibitors on the antitumor 
promotion activity of DHEA. 
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Figure 3.2.  Dose-response effects of nucleosides and (A) DHEA, (B) NBMPR, and (C) 
DPM on tumor promotion. 
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Based on these assays of functional NTs, JB6 P+ cells showed predominantly an ENT1 
transport phenotype, which may explain the higher capacity of nucleoside transport by 
the P+ cell line than the P- variant (data not shown). 
 
 Real time PCR analysis of NT mRNA expression confirmed the results of the 
functional assays of nucleoside uptake showing ENT1 as the predominant transporter, 
with very little ENT2 or CNT1/2 expression (data not shown).  For further 
characterization, real time PCR analysis of relative ENT1 expression between JB6 P+ 
(promotion sensitive) and JB6 P- (promotion resistant) variants (Figure 3.3).  Expression 
profiles between the two variants indicates that the tumor promotion sensitive (P+) cell 
line has nearly twice the levels of ENT1 transporter mRNA than the tumor promotion 
resistance (P-) cell line. 
Differential Effects of TPA on NT expression 
 Since the JB6 model of TPA-induced tumor promotion was used, the effects of 
TPA treatment on NT expression were determined for the JB6 P+ (promotion-sensitive) 
and P- (promotion-resistant) variants.  These data, summarized in Figure 3.4, show that in 
both variants, ENT1 predominates over ENT2 with TPA treatment producing increased 
expression of both ENT1 and ENT2.  The observed TPA-induced NT expression was 
more pronounced in the P+ cells.  This suggests a possible role of NT overexpression in 
the TPA-induced tumor promotion of JB6 P+ cells. 
Summary of Preliminary Data 
 Exogenous nucleosides inhibit the antitumor promotion activity of DHEA and 
nucleoside transport inhibitors.  Nucleoside transporter inhibitors show significant 
antitumor promotion activity.  JB6 P+ cells which are sensitive to tumor promotion have 
higher levels of NT expression than JB6 P- which are resistant to promotion.  Taken 
together, these preliminary results support the hypothesis that nucleoside transporters 
may be a target in chemoprevention.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.  Real time PCR analysis of ENT1 gene expression in JB6 P+ versus 
JB6 P- cells. 
31 
Effects of 8-hr PMA Treatment on Expression
of ENT1 and ENT1 RNA in JB6P- & JB6P+  Cells
P-
 8h
r w
t w
ith
 m
EN
T1
P+
 8h
r w
t w
ith
 m
EN
T1
P-
 8h
r P
MA
 w
ith
 m
EN
T1
P+
 8h
r P
MA
 w
ith
 m
EN
T
0.00
0.02
0.04
0.06
0.08
R
el
at
iv
e 
Q
ua
nt
iti
es
Effects of 8 hr TP  treat ent on expression 
of ENT1 R A in JB6 P- and JB6 P+ cells 
 Effects of 8-hr PMA Treatment on Expression
of ENT2 RNA in JB6P- & JB6P+  Cells
P-
 8h
r w
t w
ith
 m
EN
T2
P+
 8h
r w
t w
ith
 m
EN
T2
P-
 8h
r P
MA
 w
ith
 m
EN
T2
P+
 8h
r P
MA
 w
ith
 m
EN
T2
0.000
0.001
0.002
Effects f  r TP  treat e t  expression 
of ENT2 RNA in JB6 P  and JB6 P+ cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.  Real-time PCR analysis of ENT1 and ENT2 gene expression in JB6 P+ and 
JB6 P- cells and the effect of TPA (PMA) treatment. 
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CHAPTER 4:  THE ANTITUMOR PROMOTION EFFECTS OF 
DIPYRIDAMOLE AND ANALOGUES 
Introduction 
 Previous studies in our lab focused on exploring what roles nucleosides and 
nucleoside transport inhibitors (NTIs) might play in carcinogenesis.  From that work, 
nucleoside transport inhibitors were found to have significant antitumor promotion 
activity in the JB6 mouse epidermal cell carcinogenesis model.  Of the nucleoside 
transport inhibitors studied, dipyridamole appeared to have the best antitumor promotion 
activity at the concentrations tested.  In an independent study, with the aim to identify 
more potent nucleoside transport inhibitors, an extensive and structurally diverse series of 
dipyridamole analogues was synthesized and tested for NTI activity (164).   
 
With such a large library of DPM analogues at hand, it presented an opportunity 
to explore those compounds for antitumor promotion activity and subsequent structure 
activity relationships.  This chapter details the antitumor promotion effects and SAR of 
dipyridamole and 64 of its analogues.  The compounds were numbered for these studies 
as 101-164 by structural groups.  Compound 164 does not follow the sequential 
numbering by structural group because it was the last compound added to the study after 
the other analogues had been numbered. 
The soft agar colony formation assay 
 The soft-agar colony formation assay was utilized to determine the ability of 
DPM and its analogues to prevent tumor promotion.  This assay has its basis in the 
promotion phase of carcinogenesis.  JB6 cells are preneoplastic cells that respond to 
tumor promoters by irreversible induction of anchorage-independent growth.  Anchorage-
independent growth is one of the hallmarks of transformation which allows in vitro 
detection of malignant transformation of cells (20).  Transformed cells proliferate 
uncontrollably and form clusters of transformed cells (or colonies).  Cells were treated in 
the presence of the TPA and DPM analogues and allowed to grow under normal culture 
conditions for 14 days in the soft-agar media.  Colonies were counted to calculate the 
percent of colony formation based on TPA treatment alone.  Untreated (non-transformed) 
cells do not form these colonies in the soft-agar media (Figure 4.1) 
Overview of DPM analogues structural modifications 
All of the dipyridamole analogues maintained the core structure of 2,4,6,8-
tetrasubstituted-pyrimido [5,4,-d] pyrimidine structure as well as the symmetry of 
dipyridamole. There were two main regions of substituent variations, designated as 
Regions 1 and 2 in Figure 4.2.  The series of 64 DPM analogues was divided into four 
structural groups.  Compounds in Group 1 had ring substituents at the 4- and 8-position  
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Figure 4.1.  TPA-induced colony formation in JB6 P+ cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.  Structure of dipyridamole and regions of structural modifications. 
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(Figure 4.3).  In Group 2 compounds, the 4- and 8-position piperidine rings were 
substituted by acyclic tertiary amine moieties (Figure 4.4).  In Group 3 compounds, 4-,8- 
position tertiary amine was replaced by secondary amine groups (Figure 4.5).  
Compounds in Group 4 were modified at the hydroxyl groups to give ether compounds 
with the exception of Compound 158, which has locked the bis-ethanolamine into a 
morpholino ring (Figure 4.6).  Within Groups 1-3 were two subgroups to explore the 
SAR effects of bis- versus monoethanolamine at positions 2 and 6 (Type A or Type B, 
Figures 4.3-4.6).  The original series of compounds contained Type A and B of each 4-,8-
position variant.  However, only compounds that were readily available were tested, 
therefore some DPM analogues had only one subtype represented.   
Results and Discussion 
To test compounds, JB6 P+ cells (3 x 103) were exposed to 10 ng/ml TPA in soft 
agar in the presence or absence of 10 μM DPM, compounds 101-164, or vehicle (DMSO) 
for 14 days.  TPA-induced cell transformation was significantly inhibited by DPM 
(~80%).  The inhibitory effects of compounds 101-164 are compared to DPM and 
summarized in Tables 4.1 – 4.4.  Approximately 20% of the screened analogues showed 
more than 95% inhibition of TPA-induced transformation with representation from each 
structural group.  The inhibitory activities compounds range from 12-100% inhibition of 
TPA-induced transformation.  Bar graphs of these data with error bars are located in 
Figures 4.7 – 4.8. 
 
Group 1 consisted of 14 compounds with various 5- to 10-membered ring 
substitutions in the place of the piperidine ring of DPM (Table 4.1).  Only a few 
compounds had both Type A and Type B substitutions (103-104, 164-109, 112-113), but 
of those tested, there was a notable difference between the percent inhibitions of each 
subtype (Table 4.1).  There were also several compounds showing complete inhibition of  
127).  No significant trend was observed for the activities of the Type A versus Type B 
ethanolamine substitutions (Table 4.2).  The activities ranged from 30 to near 100% 
inhibition of colony formation. 
 
Group 3 contained 30 compounds, which is the largest number of analogues 
among the four groups.  In this group, the 4-, 8- position tertiary amine was replaced by a 
secondary amine to explore the SAR effects of the resulting free hydrogen (Figure 4.5).   
Substitutions ranged from monoalkyl (128-146), cycloalkyl (147-153), to aromatic rings 
(154-157).  These compounds showed a wide range of activities from 12 – 100 % 
inhibition of colony formation.  Approximately 40% of the compounds screened had 
better activity than DPM.  Within this group, there was a prominent trend of higher 
activity for the bis- versus the monoethanolamine containing compounds (Table 4.3). 
 
The smallest number of analogues was in Group 4, which presented the most 
closely related to DPM itself.  Modifications at the hydroxyl groups afforded activities 
ranging from 20-100% inhibition of tumor promotion of the 6 compounds tested. 
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Figure 4.3.  Core structures of Group 1 DPM analogues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  Core structures of Group 2 DPM analogues. 
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Figure 4.5.  Core structures of Group 3 DPM analogues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.  Core structures of Group 4 DPM analogues. 
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Figure 4.7.  Effects of DPM and analogues (101 – 131) on TPA-induced tumor  
promotion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4.8.  Effects of DPM and analogues (132 – 164) on TPA-induced tumor 
promotion. 
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Table 4.1.  Antitumor promotion activities of Group 1 DPM analogues. 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Type R1 Percent Inhibition 
DPM 
 
A 
 
N
 
 
79.5 
101 B 97.0 
102 B 
 
N
 
 
76.7 
103 A NO 70.6 
104 B 76.9 
105 A 
 
NN
 
 
51.3 
106 A 
 
BocN N
 
94.7 
107 A 
 
 
 
89.2 
108 B 
 
N
 
 
80.9 
164 A 
 
N 
 
100 
109 B 100 
110 B 
 
N
 
 
99 
111 B 
 
N
 
65.6 
112 A 
 
N
 
 
71.6 
113 B 100 
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Table 4.2. Antitumor promotion activities of Group 2 DPM analogues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3.  Antitumor promotion activities of Group 3 DPM analogues (128 – 144). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Type R1 Percent Inhibition
DPM   79.5 
114 A CH3 65.6 
115 A C2H5 
94 
116 B 37.4 
117 A nC3H7 
98.7 
118 B 59.3 
119 B nC4H9 33.9 
120 A isoC4H9 
88.2 
121 B 93.7 
122 A nC5H11 31.4 
123 A isoC5H11 31.3 
124 A CH3O(CH2)2 
66 
125 B 39.6 
126 A 43.7 
127 B 76 
Compound Type R1 Percent Inhibition
DPM   79.5 
128 A H 15.6 
129 A CH3 
12.8 
130 B 12.4 
131 A C2H5 
34.8 
132 B 41.7 
133 A nC3H7 
70.9 
134 B 69.3 
135 A isoC3H7 
84.8 
136 B 56.7 
137 A nC4H9 83.2 
138 A isoC4H9 90.6 
139 A tertC4H9 
72.0 
140 B 54.3 
141 A nC5H11 
90.3 
142 B 46.3 
143 A isoC5H11 
99.7 
144 B 95.1 
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Table 4.4.  Antitumor promotion activities of Group 3 DPM analogues (145 – 157). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.5.  Antitumor promotion activities of Group 4 DPM analogues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Type R1 Percent Inhibition
DPM   79.5 
145 A tertC5H11 
97.6 
146 B 76.8 
147 A cycloC3H5 
49.6 
148 B 35.6 
149 A cycloC4H7 90.2 
150 A cycloC5H9 
100.0 
151 B 97.2 
152 A cycloC6H11 
100.0 
153 B 50.9 
154 A  
 
 
85.7 
155 B 37.9 
156 A  
 
 
98.4 
157 B 55.0 
Compound R1 Percent Inhibition 
DPM  79.5 
158 - 45.0 
159 CHO 98.1 
160 COCH3 99.1 
161 CH3 89.1 
162 C2H5 34.2 
163 nC3H7 22.7 
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Cytotoxicity screening 
Once the series of DPM analogues was screened at 10 μM for their antitumor 
promotion effects, the data showed some compounds were able to completely inhibit 
TPA-induced transformation.  The alternative to this concept is that some of the 
compounds may be killing the cells and in turn, the antitumor promotion effects that we 
noted may have been a result of cytotoxicity.  JB6 cells are otherwise normal cells until 
treated with tumor promoters such as TPA.  Since the purpose of the soft colony agar 
assay was to determine the antitumor promotion effects of DPM and its analogues, it was 
necessary to assess if the observed antitumor promotion activities were real or just a mere 
representation of cell killing.  To ensure more accurate analysis of the data from the 
colony assay, the MTT assay of cell viability was performed to determine the effects on 
JB6 P+ cell viability.  Cytotoxic effects were quantified as percent viability of untreated 
JB6 P+ cell after treatment with 10 μM of each compound (Figures 4.9 – 4.10).  
Camptothecin, a cytotoxic alkaloid, and Ara-A, a nucleoside analog inhibitor of DNA 
polymerase, were used as positive controls for cytotoxicity.  The MTT assay of cell 
viability showed that many of the compounds were cytotoxic (< 80% viability), including 
a significant number of the analogues that showed >90% inhibition of tumor promotion 
in the screening.   
Nucleoside transport inhibition: A mechanism of antitumor promotion  
As previously discussed, the DPM analogues tested in this study were originally 
designed and screened as nucleoside transport inhibitors.  The preliminary studies on 
nucleoside transport inhibitors as potential chemopreventive agents spurred from the 
concept that neoplastic or preneoplastic cells have a higher demand for nucleic acid 
synthesis which may be prevented or delayed by the use of nucleoside transport 
inhibitors.  In a first round effort to test the nucleoside transport inhibition as a 
mechanism in the antitumor promotion activity of the DPM analogues, a correlation 
analysis of the previously collected nucleoside transport inhibition data and the antitumor 
promotion data was done by linear regression analysis.  After eliminated the cytotoxic 
compounds, there were 29 analogues remaining that were used for the regression analysis 
(Table 4.6).  The nucleoside transport inhibition assay was done using PK15 nucleoside 
transport deficient cells transfected to express ENT1 or ENT2.  Inhibition of nucleoside 
transport was measured using the standard 3H [uridine] uptake assay.  The correlation 
between antitumor promotion and nucleoside transport inhibition was higher for ENT1 
(R2 = 0.4286) than ENT2 (R2 = 0.2097) (Figure 4.11 – 4.12).  This result suggests that 
ENT1 is more likely to be involved in the antitumor promotion activity of these 
compounds than ENT2.  Based on the clustering of the compounds in the ENT1 
correlation, it is would be a reasonable prediction that compounds with greater than 60% 
inhibition of ENT1 transport will be potent inhibitors of tumor promotion (Figure 4.11).  
The clustering of the compounds in the ENT2 correlation shows that even poor inhibitors 
of ENT2 are potent inhibitors of tumor promotion (Figure 4.12).  Tables containing cell 
viability, nucleoside transport, and tumor promotion activity data for all the analogues are 
in Appendix A (Tables A.1 – A.4).  
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Figure 4.9.  Effect of DPM and analogues (101 – 135) on JB6 P+ viability 
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Figure 4.10.  Effect of DPM and analogues (136 – 164) on JB6 P+ viability. 
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Compound # % Viability
ENT1 
Uptake
ENT2 
Uptake
Tumor 
Promotion
104 71.4 58.7 33.0 76.9
105 80.0 28.9 18.3 51.3
108 99.9 83.4 33.4 80.9
113 83.4 74.5 3.7 100.0
115 83.3 88.4 75.1 94.0
116 85.9 77.4 84.0 37.4
119 82.3 31.8 84.6 33.9
121 99.5 58.8 92.6 93.7
122 79.0 19.4 5.7 31.4
123 103.1 31.3 11.8 31.3
124 100.0 68.0 77.2 66.0
126 80.6 53.2 21.0 43.7
127 82.5 7.5 5.3 76.0
128 86.0 7.3 3.2 15.6
130 81.9 30.6 -0.3 12.4
132 87.8 25.0 1.0 41.7
137 85.8 92.6 68.7 83.2
138 83.6 95.4 89.2 90.6
139 82.3 86.7 17.5 72.0
145 81.7 85.5 37.4 97.6
146 109.0 67.8 24.4 76.8
149 66.2 89.1 89.3 90.2
151 92.0 27.8 21.4 97.2
158 97.8 71.0 25.7 45.0
161 91.3 89.8 86.8 89.1
162 101.0 60.8 0.0 34.2
163 88.0 21.1 1.8 22.7
164 93.1 94.1 79.5 100.0
DPM 82.8 97.4 98.2 79.5
% Inhbition 
Table 4.6.  Summary of the nucleoside transport inhibition and antitumor promotion 
activities of DPM and noncytotoxic analogues. 
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Figure 4.11.   Linear regression of percent inhibition of ENT1 transport and percent 
inhibition of tumor promotion by DPM and analogues 
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Figure 4.12.   Linear regression of percent inhibition of ENT2 transport and percent 
inhibition of tumor promotion by DPM and analogues 
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Selection of compounds for dose-response study 
For the next phase of the study, the objective was to determine the IC50 values of 
the noncytotoxic analogues.  From the original sample of 64 DPM analogues, compounds 
with less than 80% viability were eliminated.  From the remaining compounds, those 
with % inhibition of tumor promotion greater than that of DPM (79.5%) were selected.  
The thirteen compounds selected for the dose-response study are shown in Table 4.7 
which includes the MTT and antitumor promotion activity data.  As in the correlation 
analysis from the previous section, a few compounds that did not quite pass the viability 
and/or antitumor activity screening limits for selection (104,146,149) that were kept to 
broaden the range of activity data for SAR analysis.   
Anti-tumor promotion dose response of DPM and analogues 
The soft agar colony assay was repeated in the same manner as for the 10μM 
screening, but this time we using a range of concentrations (0.01, 0.1, 1.0, 5.0, 10, and 25 
μM) for each compound.  The colonies were counted manually using inverted 
microscopy and percent inhibition values were calculated.  Soft agar colonies of the 
control and DPM treatments were stained and digital images were taken (Figure 4.13-
4.14) to represent the visible differences of dose on colony formation.  
 
Dose-response curves were plotted in GraphPad Prism 4 using the calculated 
percent inhibition of tumor promotion.  IC50 values were obtained by selecting the 
regression analysis that gave the best fit of the data (summarized in Table 4.8) and used 
to interpret structural activity relationships of these compounds. The structures and 
calculated IC50 and LogP data for tested compounds are presented based on the structural 
group to which they belong in Figures 4.15 – 4.20.   Structures of the 13 compounds 
along with IC50 data and dose curves are presented in Appendix B (Figures B.1 – B.5).  
SAR analysis 
 The 13 compounds selected for IC50 analysis were representative of the various 
structural groups in the original data set of 64 compounds.  Using DPM as the point of 
reference, a collection of structure activity relationship has been noted for DPM 
analogues using the antitumor promotion assay (summarized in Figure 4.21).  Across all 
four structural groups, the bisethanolamine substituted analogues were more potent than 
the monoethanolamine substituted analogues (Type A > Type B).  The most potent of all 
of the analogues, 145 (Type A, IC50 = 0.12 µM) contained a tert-pentyl secondary amine 
at the 4- and 8- positions followed in rank by the butyl counterparts  137 (n-butyl, IC50 = 
0.55 μM) and 138 (isobutyl, IC50 = 1.41 μM).   There was a notable 20 fold decrease in 
activity between 145 (Type A) and its monoethanolamine counterpart (146, Type B).  
However, 146 still showed enhanced potency compared to DPM (145 >> 146 > DPM) 
which suggests the tert-pentyl substitution confers enhanced activity compared to the 
pyrimidine in DPM.  Larger, flexible rings are well tolerated as substitutes for the 
pyrimidine of DPM (149 < DPM < 164).  Bisethanolamine containing DPM analogues  
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Compound % Viability  % Inhibition of Tumor Promotion
104 71.4 76.9
108 99.9 80.9
164 93.1 100.0
113 83.4 100.0
115 83.3 94.0
121 99.5 93.7
137 85.8 83.2
138 83.6 90.6
145 81.7 97.6
146 109.0 76.8
149 66.2 90.2
151 92.0 97.2
161 91.3 89.1
DPM 82.8 79.5
Table 4.7.  Summary of MTT and antitumor promotion data for selected DPM analogues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
Note:  Highlight signifies data for DPM 
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Figure 4.13.  Soft agar colony control (16 nM TPA only). 
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Figure 4.14.  DPM dose-response in the soft agar colony assay. 
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Table 4.8.  Regression equations and calculated antitumor promotion IC50 for DPM and 
analogues.  (Data presented as the mean ± standard error of the mean). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  Highlight signifies data for DPM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15.  IC50 and LogP data for DPM  
N
N
N
N
N
N
N
N
HO
OH
DIPYRIDAMOLE
OH
OH
IC50 
3.07 μM
LogP 
3.0
Regression Equation Calculated IC50 (µM) 
104 Sigmoidal-Dose Response 17.00 ± 0.54
108 Sigmoidal-Dose Response (Variable Slope) 4.86 ± 0.44
164 Sigmoidal-Dose Response 1.76 ± 0.57
113 Sigmoidal-Dose Response (Variable Slope) 5.10 ± 0.48
115 Sigmoidal-Dose Response 2.36 ± 0.48
121 Sigmoidal-Dose Response (Variable Slope) 3.88 ± ND
137 Sigmoidal-Dose Response (Variable Slope) 0.55 ± 0.471
138 Sigmoidal-Dose Response (Variable Slope) 1.41 ± 0.184
145 Sigmoidal-Dose Response 0.12 ± 0.459
146 Sigmoidal-Dose Response (Variable Slope) 2.83 ± 0.407
149 Sigmoidal-Dose Response (Variable Slope) 4.11 ± 0.103
151 Sigmoidal-Dose Response (Variable Slope) 2.77 ± 0.093
161 Sigmoidal-Dose Response (Variable Slope) 4.90 ± 0.107
DPM Sigmoidal-Dose Response (Variable Slope) 3.07 ± 0.273
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Figure 4.16.  IC50 and LogP data for DPM Analogues from Group 1.
N
N
N
N
N
NH
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N
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IC50 
5.10 μM 
LogP 
4.19
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Figure 4.17.  IC50 and LogP data for DPM analogues from Group 2. 
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Figure 4.18.  IC50 and LogP data for DPM analogues from Group 3. 
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Figure 4.19.  IC50 and LogP data for DPM analogues from Group 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20.  IC50 and LogP data for DPM analogues from Group 4. 
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Figure 4.21.  Summary of DPM and analogues antitumor promotion SAR. 
 
 
also show preference for more flexible rings at the 4- and 8-positions (108 > 113).  There 
is a similar preference for flexible substituents on the 4- and 8-position secondary amines 
(145 > 149).  With the exception of the rigid cyclobutyl substitution (149), acyclic 
secondary amines at the 4- and 8-position were more potent than DPM.  Replacing the 
free hydroxyls of DPM with methyl groups decreased the potency nearly 2 fold (DPM > 
161).   
Conclusions 
 Based on the regression analysis of inhibition of tumor promotion and inhibition 
of nucleoside transport, potent ENT1 inhibitors appear to be predictive of potent 
antitumor promotion activity.  It is unlikely that inhibition of nucleoside transport is the 
only mechanism behind the antitumor promotion activity of these compounds.  However, 
inhibition of ENT1 seems to have some significance in the chemopreventive activity of 
these compounds.  The cytotoxicity and nucleoside transport data for all of the DPM 
analogues is summarized in Appendix A. 
 
The dose-response analysis of the antitumor promotion activities of DPM and its 
analogues afforded a series of structure activity relationships which are summarized in 
Figure 4.18.  The free hydroxyls of DPM are required for optimal activity and may offer 
insight to the mechanism of these compounds upon further analysis.  The secondary 
amines at the 4- and 8-position also have free hydrogens that may be involved in 
hydrogen bonding that influences the antitumor promotion activity.  Compound 145 was 
the most potent of the noncytotoxic DPM analogues with an IC50 of 0.12 μM, which is 25 
fold more potent than the parent compound DPM (IC50 = 3.07 μM).  Compound 145 is 
also potent inhibitor of ENT1 nucleoside transport (Ki = 14.7 nM), which may be 
involved in the mechanism of antitumor promotion of this compound.  Compound 145 is 
a novel DPM analogue with potential use as a chemopreventive agent.  Overall, this SAR 
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data will aid in the next phase of drug design in search for even more potent 
chemopreventive agents. 
Limitations of the Present Study 
In the soft agar colony assay set-up, the treatments with the compounds were done 
in duplicate, which does not provide strong statistical basis for the data.  However, to 
account for this limitation, colonies were counted twice for several of the samples to 
verify the consistency of the counting technique. 
 
JB6 cells were treated with DPM and analogues for 48 hours in the cytotoxicity 
studies.  However, in the soft-agar colony assay, the cells are incubated with compounds 
in the presence of TPA for 14 days.  Therefore, cytotoxic effects that occur after 48 hours 
were not considered in this study and should be considered in future assay design. 
Materials and Methods 
Reagents 
  Dipyridamole (DPM), 12-O-tetradecanoyl-phorbol-13-acetate (TPA), dimethyl 
sulfoxide (DMSO), heat-inactivated fetal bovine serum (HI-FBS), and Trypsin-EDTA 
(0.25%) solution were obtained from Sigma.  Phosphate buffered saline (PBS) was 
diluted from a 10 X PBS (pH 7.4, GIBCO) stock to a 1 X PBS solution for cell culture.  
Minimum essential medium (MEM) powder (containing Earle’s salts and L-glutamine), 
and gentamicin were purchased from GIBCO.  For cell culture, 1 L of 1 X MEM was 
prepared by diluting MEM powder in deionized (dI) H2O following the manufacturer’s 
protocol.  All cell culture materials were either pre-sterilized by the manufacture or 
autoclaved prior to use.  Cell culture media was sterile-filtered using 0.22 μm cellulose 
acetate bottle top filter.  Low-melt agarose powder was purchased from American 
Bioanalytical.  The JB6 P+ mouse epidermal cell line, C141, was purchased from 
American Type Culture Collection (ATCC).  DPM analogues (101-164) were prepared 
previously (198) and 10 mM stock solutions in DMSO were used for all studies.  
Cell culture 
The JB6 P+ mouse epidermal cell line, C141 was cultured at 37 °C, 5% CO2 in 
MEM containing 5 or 10 % FBS, 2 mM L-glutamine and 25 μg/ml gentamicin.  Cells 
were cultured in monolayer in T25, T75, or T150 flasks and passaged at 70-80% 
confluence.  First, cells were washed with 10 ml of 1 X PBS followed by vacuum 
aspiration.  To detach the cells for passaging (or for soft-agar colony assay), 1-2 ml of 
trypsin-EDTA (0.25%) was added to the monolayer cells and placed at 37 °C, 5% CO2 
for 5-10 min.  After incubation, 8-9 ml fresh culture media was added and the detached 
cells were collected and centrifuged (20 °C, 5-10 min, 1000 rpm).  The resulting cell 
pellet was homogenized in fresh culture media and split into new culture flasks. 
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Soft agar colony formation assay 
A concentrated solution of JB6 P+ cell culture media (2 X MEM) was prepared by 
diluting MEM powder in deionized H2O supplemented with 10 or 20% heat inactivated 
FBS and 25 μg/ml gentamicin to a volume of to 500 ml.  A 1.6% agar was prepared by 
adding 1.6 g low-melt agarose powder to 100 ml deionized H2O with subsequent 
sterilization by autoclave.  All solutions and reagents were kept at 37 °C while setting up 
the agar plates. 
 
A solution of 2 X MEM media containing 32 nM TPA with or without 2 times the 
final concentrations of the compounds was prepared (designated as 2 X Sample 
Medium). The bottom layer was prepared by mixing 2 X MEM with 1.6% agar (1:1).  In 
6-well plates, 1 ml of this solution was added to each well and allowed to gel at 4 °C for 
20-30 min.  Plates were warmed at 37 °C for 15 minutes before adding the top layer.  The 
top layer solution (10 ml) consisted of 1.6% Agar, 2 X Sample Medium, and dI H2O 
(1:2:1).  This solution was kept warm at 37 °C while preparing the JB6 P+ cells.  Cells 
were trypsinized, pelleted, and resuspended to a concentration of 3 x 105cells/ml in 1 X 
MEM.  100 μl of this dilution of cells was added to the top layer solution and mixed well.  
1 ml of this top layer solution with cells was added to the pre-warmed bottom layer and 
allowed to gel at 4 °C for 15-20 min.  
 
The final working concentrations were:  Top Layer - 3 x 103 cells in 1 ml of 
0.4% agar medium containing 5 or 10% FBS, 16 nM TPA, and 0.01 – 25 μM DPM 
analogues; Bottom Layer - 1.5 ml of 0.8% agar medium.  The DPM analogues were 
tested in duplicate.  Soft-agar colony plates were incubated at 37 °C, 5% CO2 for 14 days, 
and the anchorage-independent colonies were counted manually under an inverted 
microscope. Colonies with more than 8 cells were scored.  Some plates were stained with 
MTT (0.5 mg/ml in PBS) after manual counting for visual enhancement of the digital 
images.  The efficiency of DPM and analogues inhibition of TPA-induced cell 
transformation is expressed as a percentage of the transformation frequency when the 
cells were treated with TPA alone. 
MTT assay of cell viability 
JB6 P+ cells were trypsinized, pelleted, and resuspended in 1 X MEM.  In 96-well 
plates, 100 μl 1 X MEM containing 5 x 103 cells were seeded in each well.  Cells were 
incubated for 12-16 hrs and then treated with 10 μM of DPM and analogues or vehicle, 
DMSO, in 100 μL of 1 X MEM for 48 hours.  Subsequently, 10 μl of 5 mg/ml 
methylthiazolyldiphenyl-tetrazolium bromide (MTT) in PBS was added to each well, and 
then incubated for 4 hrs at 37°C.  The yellow MTT is reduced to purple formazan in the 
mitochondria of living cells (cell viability). The media/MTT solution was removed by 
blotting and the formazan crystals were dissolved in 100 μl DMSO.  The absorbance was 
quantified at 570 nm using a microplate reader (SpectraMax M2, Molecular Devices). 
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IC50 calculations 
IC50 values were determined using the GraphPad Prism 4 software.  Data were 
input as concentration (nM) and percent inhibition.  The software transform feature was 
used to convert the concentration to Log (concentration) [X = Log(X)].  These 
transformed data were then subjected to the software’s built-in nonlinear regression 
(curve fit) analysis.  Within the analysis, several equations were tried to provide the 
“best-fit” curves for the data.  These curves were plotted and the equations that gave 
curves most representative of the data were selected and the respective calculations to 
compute the IC50 and standard error values.   
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CHAPTER 5:  THE EFFECTS OF DIPYRIDAMOLE ON MAP KINASES 
Introduction 
 A large number of dietary factors, the most commonly studied agents in 
chemoprevention, are reported to have inhibitory effects on tumor-promoter induced-
MAP kinase activation.  For example, anthocyanidins, found in red cabbage, red grapes, 
purple sweet potatoes, and berries, inhibit tumorigenesis by inhibition of Erk and Jnk 
MAPKs (199).  Green and black tea polyphenols such as epigallocatechin-3-gallate 
(EGCG) and theaflavins inhibit Jnk but not Erk activation (200).  A number of 
chemopreventive agents, including the above mentioned, subsequently modulate the 
downstream transcription factor, AP-1.  For instance, the anti-tumor promotion effect of 
equol, a soybean metabolite, is a result of inhibition of AP-1 via the MAPK pathway 
(201). 
 
  In previous studies, an AP-1-SEAP reporter stable transfectant JB6 cell line was 
established.   Using this reporter cell line, DPM was found to inhibit AP-1 activity in a 
dose-dependent manner (Figure 5.1).  Therefore, MAPKs were a feasible upstream signal 
potentially involved in the mechanism of DPM antitumor promotion.  The studies in this 
section assessed the roles of p38 and Erk MAPKs in the observed AP-1 inhibition.  
Transcriptional activation of Elk-1 requires phosphorylation by MAPKs  (52).  Therefore, 
the role of Elk-1 was also studied.  
Results and Discussion 
Time kinetics of TPA-induced MAPK signaling in JB6 P+  
The time course of TPA-induced MAPK activation was first analyzed to determine what 
time period of TPA treatment would afford significant induction of MAPK activity so as 
to analyze the effects of DPM.  JB6 cells were first serum-starved (0.1% FBS) for 48 
hours.  Fetal bovine serum (FBS) supplemented in the cell culture media contains growth 
factors, cytokines, and hormones, which can induce MAPK signaling.  Growing the cells 
in minimal sera conditions minimizes the background MAPK activation from these 
components. 
 
After starving, 16 nM TPA was added at times ranging from 5 minutes to 24 
hours, and the resultant induction of MAPKs was assessed by Western blotting analysis.  
For all of the MAPK studies, the negative control samples were treated with vehicle 
(DMSO) while the positive control was treated with TPA.  ImageJ Analysis (NIH 
software) was used to quantify and normalize the protein bands.  Based on the results 
from the time-course analysis (Fig 5.2), 1 hour TPA treatment gave the highest MAPK 
inductions.   However, significant induction was also observed as early as 5 min for all 
proteins except p38.  For the studies with DPM, cells were treated 1 hour to minimize 
technical errors. 
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Figure 5.1.  DPM dose-dependent inhibition of AP-1 transactivation. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  This value is slightly higher because of the background signal detected in ImageJ band analysis 
 
 
Figure 5.2.   Time course of TPA-induced MAPKs. 
TPA (16 nM)
_______________________________________________________
C     24h   12h    8h     4h     1h      30’ 5’
p-Erk
p-p38
1.0  1.2   0.8  0.9   0.8   1.5   1.1   1.6
1.0  4.5  4.3  6.1   6.8  12.8  12.5  14.1
β-actin
TPA (16 nM)
_______________________________________________________
C      24h   12h    8h     4h     1h      30’ 5’
p-Elk-1
β-actin
Erk
p38
1.0   2.2   2.2   2.5   3.1   3.1   2.3   1.3
1.0* 0.5  0.5  0.3   0.2 0.9   0.3   1.4
1.0   1.3   1.1   1.2   1.0   1.1   0.5   1.3
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Effect of DPM pretreatment on TPA-induced MAPKs 
 The purpose of the dose-response study was to determine the effects of varying 
concentrations of DPM (0.01 – 25 μM) on MAPK signaling. JB6 P+ cells were pretreated 
with DPM for 1 hour.  Cells were subsequently stimulated with TPA for 1 hour as 
determined from the time-course analysis (Figure 5.3).   
 
 The negative control samples were not treated with TPA or DPM while the 
positive control was treated with TPA.  The positive control served as the reference point 
to analyze the effects of DPM pretreated samples. Compared to the cells treated with 
TPA, DPM treatments showed decrease induction of Erk except for the 1 μM treatment.  
There was no clear trend in this inhibitory effect as shown by the line graph of the fold 
induction values (Figure 5.4).  The most significant inhibition of Erk was at 0.1 and 10.0 
μM at which Erk induction was returned to its basal untreated levels. 
 
All of the DPM concentrations augmented the activation of Erk, measured by 
phosphorylation of Erk (p-Erk) giving protein levels much higher than TPA stimulation.  
The highest activation was observed with 0.01 and 1.0 μM DPM pretreatment (Figure 
5.5). Taken alone, DPM induction of Erk does not correlate to inhibition of MAPK 
signaling.  The level of Erk induction was a reference point to ensure the level of 
phosphorylated proteins is not just a consequence of protein levels.  Normalized data 
showed that activation of p-Erk was independent of Erk induction (Figure 5.3).  
Therefore, the DPM is clearly not an inhibitor of TPA-induced Erk induction based on 
the 1 hour pretreatment set-up.  To the contrary, DPM showed a dose-dependent 
activation of p-Erk, with the lowest concentration giving the most activation. There was a 
dose-dependent inhibition of p38 activation with 25 μM DPM treatment giving a return 
to basal levels (Figure 5.6). 
Effect of DPM pretreatment on TPA-induced ENT1 
 The PCR analysis of ENT1 in Chapter 3 showed that TPA stimulates the 
expression of ENT1 mRNA.  In this study, ENT1 expression was analyzed in response to 
DPM and TPA stimulation.  Cells were pretreated with DPM followed by 1 hour of TPA-
stimulation.  JB6 P+ cells stimulated for 1 hr resulted in induction of ENT1, while 
pretreatment with various concentrations of DPM did not show any significant changes in 
ENT1 levels (Figure 5.7). 
Dose effects of DPM on MAPK signaling 
 Based on the findings from the DPM dose-response study, it seemed that DPM 
was activating Erk independent of TPA.  To determine the MAPK stimulation of DPM 
itself, JB6 P+ cells were pretreated with or without 10 μM DPM followed by stimulation 
with 16 nM TPA (Figure 5.8).  Erk induction by DPM alone was equivalent to that with 
TPA stimulation.  DPM pretreatment followed by TPA stimulation resulted in increased 
Erk induction.  Phosphorylation (activation) of Erk by DPM alone was much lower than  
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Figure 5.3.  DPM dose effects on TPA-induced MAPKs. 
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Figure 5.4.  DPM dose effects on TPA-induced Erk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
DPM Concentration (µM) 
p-Erk
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
0 0.01 0.1 1 5 10 25
Fo
ld
 In
du
ct
io
n
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.  DPM dose effects on TPA-induced Erk activiation. 
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Figure 5.6.  DPM dose effects on TPA-induced  p38 activation. 
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Figure 5.7.  DPM dose effects on TPA-induced ENT1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8.  Effects of DPM and TPA on MAPKs. 
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that of TPA.  Pretreatment with DPM showed no significant difference between DPM 
and TPA-induced p-Erk (Figure 5.8). 
 
The effect of DPM on Elk-1, a downstream target of Erk, was also studied.   JB6 
P+ treated with DPM alone showed a similar induction of Elk-1 protein compared to TPA 
alone.  As seen with Erk, pretreatment with DPM followed by TPA stimulation increased 
this induction.  DPM alone stimulated Elk-1 activation, but less than TPA.  There was an 
additive effect on Elk activation when cells were treated with both TPA and DPM. This 
activation was independent of Elk-1 protein levels (Figure 5.9).  The effects on p38 were 
also determined.  DPM alone or combined with TPA showed similar activation of p38, 
which was independent of p38 protein induction (Figures 5.8 – 5.9).  This result differs 
from that in the previous dose-response study in which DPM inhibited p-p38 activation.  
This is likely a due to the difference in the experimental protocol.  In the first dose-
response analysis DPM was added to the cells in a premixed media solution and 
incubated for 1 hr.  This solution was removed prior to adding a premixed media solution 
with TPA.  In this study looking at the effects of DPM itself on MAPKs, TPA was added 
directly to the premixed solution containing DPM.  Therefore, the cells were exposed to 
DPM for an additional hour and the observed p-p38 activation likely reflects the time 
effects of DPM incubation on MAPKs. 
Discussion 
DPM and nucleoside transport inhibition 
To begin with, DPM is a nucleoside transport inhibitor.  In previous work, the 
tumor promoter, TPA induced expression of ENT1 mRNA (Figure 3.4).  The hypothesis 
was that preneoplastic cells require higher amounts of nucleosides based on the demand 
to produce RNA and DNA.  The observed increase in ENT1 mRNA expression in 
response to TPA suggests that this transformation signaling induces NT expression to 
meet this demand.  Therefore, by inhibition of nucleoside transport, DPM can inhibit or 
prevent the preneoplastic-to-neoplastic transformation.   
 
Tamoxifen, an anti-estrogen cancer drug and chemopreventive agent, has been 
reported to influence NT expression.  ENT1 protein expression is downregulated in 
tamoxifen treated MCF-7 human breast cancer cells and can be reversed by treatment 
with estradiol (197).  Tamoxifen treatment also inhibits ENT1 function in MCF-7 cells 
(202).  Tamoxifen has exhibited chemopreventive activities in clinical trials as well.  The 
Breast Cancer Prevention Trial (BCPT) assessed the effects of tamoxifen on women at 
high risk for developing breast cancer.  The study was terminated upon recognizing 
nearly all the women receiving tamoxifen showed 50% fewer invasive breast cancer 
diagnoses compared to those receiving placebo. The Food and Drug Administration 
(FDA) has approved tamoxifen for breast cancer prevention, however, side effects 
including endometrial cancer, pulmonary embolism, and deep vein thrombosis preclude 
tamoxifen use in certain populations (203,204). 
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Figure 5.9.  Comparison of MAPK induction versus activation by DPM and TPA. 
TPA
DPM
DPM + TPA
Erk
p-Erk
p38
p-p38
Elk1
p-Elk1
0
1
2
3
4
5
6
7
68 
The chemopreventive activity of tamoxifen may be a attributed to regulation of 
ENT1.  By downregulating ENT1 protein and function, it mimics the action of NTIs in 
that it decreases the ability of preneoplastic cells to use salvage pathways to produce the  
nucleotides needed for aberrant growth and proliferation.  Tamoxifen is also a PKC 
inhibitor which may underlie the regulation of ENT1 by tamoxifen. 
 
A common factor in the TPA and tamoxifen mediated regulation of NTs is PKC.   
As it relates to NTs, acute stimulation of PKC has been shown to cause rapid elevation of 
hENT1 in cultured human cancer cell lines, MCF-7 and HeLa.  In this same report down-
regulation of PKC resulted in decreased hENT1 transport (136).  Inhibitors of PKC have  
shown inhibition of nucleoside transport in K562 human erythroleukemia cells (152).     
All three of these cell lines have predominantly equilibrative nucleoside transporters with 
ENT1 dominating, which may be the link between PKC inhibition and antitumor 
promotion (202,205,206). 
 
TPA-induced tumor promotion involves binding to and activation of its 
intracellular receptor PKC.  Taken together with the previous reports, TPA-induced NT 
expression observed in our study is likely mediated by TPA activation of PKC.  Also, the 
ability of DPM to inhibit this is similar to that observed with the chemopreventive agent, 
tamoxifen.  This suggests that inhibition of PKC and its regulatory effects on NTs may be 
a potential target for the design of chemopreventive agents. The involvement of PKC was 
not analyzed in this study, but this should be considered.  In terms of targeting NTs, their 
regulation by PKC adds to their potential as targets for chemoprevention. 
 
Finally, it is noteworthy to mention that a few chemopreventive dietary factors 
have shown inhibition of nucleoside transport activity.  Green tea polyphenols have 
shown potent inhibition of nucleoside transport and TPA-induced tumor promotion (207-
209)  One particular tea polyphenol, EGCG, also inhibited the activation of PKC by 
teleocidin. 
DPM and MAPKs 
MAP kinases are important signaling molecules known to mediate AP-1 function 
(210).  Inhibition of MAPKs is responsible for inhibition of cell transformation via 
inhibition of AP-1 transactivation (211). The purpose of this study was to determine if 
MAPKs are involved in the antitumor effects of DPM in the JB6 model. Based the data 
from previous studies, DPM inhibits AP-1 transactivation.  Since MAPKs mediate AP-1, 
the postulate was that DPM inhibits MAPKs.  In this study, we found that DPM itself was 
actually an activator of Erk and Elk MAPKs.  Pretreatment of the JB6 P+ cells with DPM 
did not inhibit TPA induced Erk or Elk-1, but adds to this activation.  Therefore, DPM 
pretreatment does not inhibit AP-1 via Erk or Elk-1 within the observed times of this 
study.  
 
We did, however, observe a dose-dependent inhibition of p-p38.  Recent studies 
in RAW 264.7 cells report DPM to activate MAPK phosphatase (MKP-1).   MKP-1 is a 
potent inhibitor of p38 MAPK function.  Our results from 1 hour pretreatment with DPM 
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agree with this finding.  p38 MAPK is a key player in EGF-induced promotion in JB6 
cells,  as well as a regulator of AP-1 binding and NF-κB signaling (NF-κB discussed in 
the next section) (30).  Therefore, the inhibition of AP-1 and possibly NF-κB is likely one 
mechanism of antitumor promotion by DPM. 
DPM and inhibition of ROS 
All aerobic organisms form and degrade reactive oxygen species (ROS) (212). 
Oxidative metabolism in the mitochondria, metabolic processes, and inflammation are 
sources of endogenous ROS (213). Detoxification and metabolism of drugs, hormones, 
and other xenobiotics are exogenous sources of ROS (214,215).  ROS produced by these 
processes include the superoxide anion radical, hydrogen peroxide, and the hydroxyl 
radical, all of which contain unpaired electrons.  Cellular defense and redox systems are 
responsible for the regulation of ROS levels. At homeostatic levels, ROS has beneficial 
physiologic uses including intracellular signaling and redox regulation (212).  However,  
if these regulatory antioxidant systems are overcome by excessive ROS, it may result in 
damage to critical macromolecules such as DNA, proteins, carbohydrates and lipids 
(215).  
 
TPA treatment in JB6 P+ cells leads to the generation of  ROS, which stimulates 
cell growth in soft agar or in monolayer (216).  TPA-induced tumor promotion requires 
elevated levels of superoxide anion (216,217).  DPM and analogues have been shown to 
inhibit lipid peroxdiation in mitochondria (218).  DPM has been reported to act as a ROS 
scavenger of superoxide and hydroxical radicals in vitro (219,220).  Other antioxidant 
mechanisms of DPM include breaking free radical chain reactions and electron transfer 
reactions (221,222).   ROS is a major regulator of NF-κB and in turn, tumor promoter 
induced transformation (223).  Therefore, based on the antioxidant properties of DPM, 
inhibition of ROS may be a key mechanism of its antitumor promotion activity in the JB6 
model.   
DPM and inhibition of NF-κB 
Nuclear factor kappa B (NF-κB) is a downstream target of AP-1 transactivation 
the JB6 model.  NF-κB  plays a key role in tumor promoter induced transformation 
response (224).  Using the JB6 model, it was determined that the JB6 P- tumor promotion 
resistant phenotypes was due to failure to activate p65, a member of the NF-κB family of 
transcription factors(225).  Therefore p65 is essential for TPA-induced transformation in 
P+ cells.   
 
In a study aimed to probe the anti-inflammatory mechanisms of DPM, it was 
observed that DPM inhibits NF-κB signaling.  In RAW 264.7 cells, DPM inhibits NF-κB 
specific DNA binding as well as LPS-induced NF-κB activation. This is attributed to the 
ability of DPM to inhibit the translocation of p65 from the cytosol to the nucleus. 
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Another report claims DPM can be used in combination with corticosteroids as 
treatment for inflammatory disorders such as rheumatoid arthritis.  This effect is 
attributed to the inhibition of TNF-α, an inflammatory cytokine, by DPM (226).  TNF-α 
is a tumor promoter used in the JB6 model and required NF-κB for the transformation 
response (225).  Although these studies were not done in the JB6 with TPA-induced 
transformation, this shows the possible involvement of NF-κB in the antitumor 
promotion activity of DPM.    
Conclusions 
AP-1 transactivation is pivotal in TPA-induced tumor promotion. The nucleoside 
transport inhibitor, dipyridamole, inhibits AP-1 transactivation in a dose-response 
manner.    Mechanistic studies have revealed that inhibition of the p38 MAPK activation 
is one mechanism by which DPM inhibits AP-1.  Erk and Elk-1 MAPKs did not show 
any correlation with DPM inhibition of AP-1.   This study and others show connections 
between DPM and three major mediators in TPA-induced tumor promotion: AP-1, NF-
κB, and ROS.  We have shown inhibition of AP-1 activity in the JB6 tumor promotion 
model directly.  Others have shown inhibitory effects of DPM on NF-κB and ROS, which 
warrants future investigation in the JB6 model.  Inhibition of nucleoside transport shows 
potential as a novel target in chemoprevention as evidenced by the ability of DPM and 
other nucleoside transport inhibitors to hinder tumor promotion.   However, it should be 
noted that the expression profile and function of nucleoside transporters must be 
determined in each model in which these proteins are intended chemoprevention targets.   
Overall, these data provide mechanistic insights into the potent chemopreventive activity 
of DPM (Figure 5.10). 
 
In regards to the therapeutic potential of DPM in chemopreventive therapy, a few 
factors must be considered.  DPM has multiple targets (nucleoside transporters, 
phosphodiesterase, prostacyclin, etc) and the long term effects of these interactions may 
prove to negate the chemopreventive benefits upon clinical studies.  In addition to the 
broad pharmacologic effects of DPM, it also has high serum binding giving it a poor 
pharmacologic profile.  Therefore, the pursuit of more potent chemopreventive DPM 
analogues such as Compound 145 will allow the design of agents with more mechanistic 
selectivity and increased pharmacologic efficacy. 
Future Directions 
Time course of DPM chemoprevention 
In this study of the chemoprevention mechanism of DPM, JB6 P+ cells were 
pretreated with DPM for 1 hr followed by induction with TPA.  It is clear that DPM in 
the presence of TPA was able to inhibit transformation in the 14 day colony assay.   
However, the time effects of DPM on MAPK activation are not known.  To study this, 
JB6 P+ cells will be treated with selected concentrations of DPM at set times before, 
simultaneously, or after induction with TPA.  This analysis will help elucidate at what  
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Figure 5.10.  Potential mechanisms of DPM in chemoprevention.   
 
 
time DPM maximally inhibits tumor promotion and may offer further insight into its 
mechanism.   
DPM effects on AP-1 DNA binding 
 Inhibition of AP-1 transactivation by DPM may be a result of inhibitory effects on 
AP-1 DNA binding.  This can be analyzed by electrophoretic mobility shift assay 
(EMSA).   JB6 P+ cells will be pretreated with various concentrations of DPM at set 
times prior to stimulation with TPA.   Following TPA stimulation, collected nuclear 
protein extracts will be analyzed for AP-1 DNA binding.  DPM effects on AP-1 binding 
will offer further mechanistic insight. 
DPM effects on TPA-induced NF-κB activity and DNA binding 
 There are several literature reports suggesting DPM inhibits NF-κB.  Since NF-
κB is important in tumor promotion, it is a reasonable target to investigate.  DPM effects 
on NF-κB transactivation and binding can be done in the same manner as done for AP-1.   
DPM effects on ROS 
 TPA induction of ROS is important of tumor promotion and DPM has reported 
antioxidant properties.  ROS can be measured after pretreatment of JB6 P+ cells with 
DPM followed by TPA stimulation using the fluorescent probe dichlorofluorescein 
diacetate (DCFDA).  DCFDA becomes trapped in cells after passive diffusion.  In the 
presence of intracellular ROS, DCFDA is oxidized to a fluorescent product that can be 
monitored using a fluorescence detection method of choice. 
 
DPM DPM 
DPM 
DPM 
Observed inhibition 
Proposed inhibition 
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DPM effects on EGF, TNF-α, and UV-induced transformation  
 EGF, TNF-α, and UV-induced tumor promotion are more representative of the 
causative agents of cancer in humans than TPA.  They each also elicit different signaling 
mechanisms (some of which are common between them), but each signaling cascade 
offers insight into the particular aspects of carcinogenesis within certain cancer 
populations.  For instance, UV is a causative agent in skin cancer development.  
Evaluating the effect of DPM under different tumor-promoter induced signaling will 
further the understanding of the chemopreventive effects of DPM and also help determine 
its potential in clinical settings. 
DPM chemoprevention in vivo  
 To study the effects of DPM in vivo, SENCAR (sensitivity to carcinogenesis) 
mice can be used.  These mice are bred for sensitive to DMBA-initiation-TPA-promotion 
carcinogenesis model.   In this setting, a single dose of carcinogen (DMBA) is applied 
topically, followed by repeated application of promoter (TPA).  This treatment protocol 
results in visible tumors on the mouse skin.  To test DPM in chemoprevention, it should 
be added during the promotion phase.  Any chemopreventive effects (measured by skin 
papilloma incidence) of DPM would suggest its potential in the prevention of skin cancer. 
Mechanism studies on the novel DPM analogue, compound 145 
From the SAR studies presented in Chapter 4, compound 145 shows more potent 
antitumor promotion activity than DPM.  This warrants further investigation into the 
mechanism of this compound.  All of the studies done with DPM should be done with 
145 to compare the resulting mechanisms.   
Materials and Methods 
Reagents 
Dipyridamole (DPM), 12-O-tetradecanoyl-phorbol-13-acetate (TPA), dimethyl 
sulfoxide (DMSO), heat-inactivated fetal bovine serum (HI-FBS), Trypsin-EDTA 
(0.25%) solution, and bovine serum albumin (BSA) were obtained from Sigma.  
Phosphate buffered saline (PBS) was diluted from a 10 X PBS (pH 7.4, GIBCO) stock to 
a 1 X PBS solution for cell culture.  Minimum essential medium (MEM) powder 
(containing Earle’s salts and L-glutamine), and gentamicin were purchased from GIBCO.  
For cell culture, 1 L of 1 X MEM was prepared by diluting MEM powder in deionized 
H2O following the manufacturer’s protocol.  All cell culture materials were either pre-
sterilized by the manufacture or autoclaved prior to use.  Cell culture media was sterile-
filtered using 0.22 μm cellulose acetate bottle top filter.  The JB6 P+ mouse epidermal 
cell line, C141, was purchased from American Type Culture Collection (ATCC).   Erk, p-
Erk, p38, p-p38, Elk-1, and p-Elk-1 antibodies were obtained from Cell Signaling.  RIPA 
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lysis buffer with protease inhibitors was purchased from Santa Cruz.  BCA protein assay 
buffers were purchased from Pierce.  Protein gels, Tris-buffered saline (TBS), and 
Laemmli sample buffer were purchased from Bio-Rad.  Enhanced chemiluminescence 
detection solution (ECL) was purchased from GE-Amersham. 
Cell culture 
The JB6 P+ mouse epidermal cell line, C141 was cultured at 37 °C, 5% CO2 in 
MEM containing 5 or 10 % FBS, 2 mM L-glutamine and 25 μg/ml gentamicin.  Cells 
were cultured in monolayer in T25, T75, or T150 flasks and passaged at 70-80% 
confluence.  First, cells were washed with 10 ml of 1 X PBS followed by vacuum 
aspiration.  To detach the cells for passaging (or for soft-agar colony assay), 1-2 ml of 
trypsin-EDTA (0.25%) was added to the monolayer cells and placed at 37 °C, 5% CO2 
for 5-10 min.  After incubation, 8-9 ml fresh culture media was added and the detached 
cells were collected and centrifuged (20 °C, 5-10 min, 1000 rpm).  The resulting cell 
pellet was homogenized in fresh culture media and split into new culture flasks. 
Preparation of cytosolic extracts 
 JB6 P+ cells were cultured in 6-well dishes (1.5 x 105 cells per well) for 24 h.  
After which, the cells were starved in 0.1% FBS-MEM for 48 h to eliminate the influence 
of FBS on MAPK activation.  The cells were then treated in triplicate with or without 
DPM for 1 h and then treated with TPA (10 ng/ml) at designated times.  The cells were 
scraped and lysed using RIPA lysis buffer with protease inhibitors followed by sonication 
at 4 °C.  Homogenates were centrifuged at 10,000 x g for 20 min at 4 °C.  The resulting 
supernatant was collected as the cytosolic extract and protein was quantified using BCA 
analysis following the manufacturer’s protocol. 
Immunoblotting 
 For immunoblot analysis, 10 μg of each protein lysate was denatured in Laemmeli 
sample buffer (1:1) by boiling for 5 min.  Denatured proteins were then loaded on 12% 
Tris-HCl gels for SDS-PAGE analysis.  The gels were run for 1 hr at 135 V (constant 
voltage).  The separated proteins were transferred onto a PVDF membrane (100 V, 1 hr, 4 
°C).  The membranes were then blocked with 5% nonfat milk powder (w/v) in TBS/0.1% 
Tween-20 (TBST) for 1-2 h at room temperature.  Following the block, membranes were 
washed 3 times for 10 min (3 x 10 min) in TBS/0.1% Tween-20.  Membranes were then 
probed with specific primary antibodies in antibody dilution buffer (TBST/ 5% BSA) 
overnight at 4 °C.  After the primary antibody incubation period, membranes were 
washed in TBST (3 x 20 min) followed by incubation with the appropriate HRP-
conjugated secondary antibody in blocking buffer for 1 hr.  Membranes were washed 
again (3 x 10 min, TBST) and incubated with 6 ml ECL solution for 5 min.   Protein 
bands were visualized by exposing the membranes to BioMax maximum sensitivity 
autodradiography film in an autoradiography cassette in the dark room.  The film was 
developed in a film processor (Kodak X-OMAT 2000A). 
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ImageJ analysis 
The developed immunoblot films were scanned and the images uploaded to 
ImageJ (NIH software).  Protein bands from immunoblotting were quantified following 
software instructions. For each protein band, the value obtained from ImageJ was divided 
by the value of the sample loading control (β-actin) from the same lane on the protein gel 
to normalize the data.  For the untreated control, this normalized value (Y) was then 
designated as 1.0 (Y/Y) and the remaining protein sample values (Z) were divided by the 
value of the untreated control (Z/Y) to give the fold induction values.   
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Compound # % Viability  Std. Dev ENT1 Uptake ENT2 Uptake
Tumor 
Promotion
101 60.22 0.04 85.7 66.0 97.0
102 65.70 0.03 70.5 24.0 76.7
103 70.89 0.04 88.4 81.7 70.6
104 71.44 0.06 58.7 33.0 76.9
105 80.04 0.06 28.9 18.3 51.3
106 69.34 0.01 89.2 72.3 94.7
107 54.47 0.04 64.8 19.5 89.2
108 99.91 0.03 83.4 33.4 80.9
109 50.59 0.10 94.1 75.9 100.0
110 23.65 0.02 88.8 65.9 99.0
111 72.32 0.04 36.3 50.6 65.6
112 73.39 0.09 88.0 32.4 71.6
113 83.39 0.09 74.5 3.7 100.0
ARA-A 60.81 0.01 --- --- ---
CAMPTO 43.30 0.01 --- --- ---
DPM 82.78 0.02 97.4 98.2 79.5
% Inhibition
APPENDIX A:  DATA TABLES USED FOR REGRESSION ANALYSIS 
Table A.1.  Cytotoxicity, nucleoside transport inhibition, and antitumor promotion data 
for Group 1 DPM analogues. 
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Compound # % Viability  Std. Dev ENT1 Uptake ENT2 Uptake
Tumor 
Promotion
114 72.78 0.03 83.2 77.2 65.6
115 83.25 0.07 88.4 75.1 94.0
116 85.93 0.04 77.4 84.0 37.4
117 62.99 0.04 88.9 71.5 98.7
118 41.72 0.02 51.8 40.5 59.3
119 82.31 0.06 31.8 84.6 33.9
120 44.28 0.03 84.0 56.3 88.2
121 99.49 0.10 58.8 92.6 93.7
122 79.00 0.08 19.4 5.7 31.4
123 103.07 0.11 31.3 11.8 31.3
124 100.04 0.01 68.0 77.2 66.0
125 77.01 0.02 64.3 69.2 39.6
126 80.56 0.00 53.2 21.0 43.7
127 82.45 0.08 7.5 5.3 76.0
ARA-A 60.81 0.01 --- --- ---
CAMPTO 43.30 0.01 --- --- ---
DPM 82.78 0.02 97.4 98.2 79.5
% Inhibition
Table A.2.  Cytotoxicity, nucleoside transport inhibition, and antitumor promotion data 
for  Group 2 DPM analogues. 
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Compound # % Viability  Std. Dev ENT1 Uptake ENT2 Uptake
Tumor 
Promotion
128 85.99 0.15 7.3 3.2 15.6
129 61.26 0.04 52.7 2.7 12.8
130 81.92 0.10 30.6 -0.3 12.4
131 71.05 0.10 89.5 35.6 34.8
132 87.77 0.03 25.0 1.0 41.7
133 77.39 0.08 89.7 71.1 70.9
134 70.62 0.04 68.5 26.5 69.3
135 73.60 0.02 92.3 82.8 84.8
136 77.75 0.01 57.1 10.8 56.7
137 85.76 0.03 92.6 68.7 83.2
138 83.58 0.02 95.4 89.2 90.6
139 82.29 0.10 86.7 17.5 72.0
140 76.74 0.01 79.2 23.3 54.3
141 53.57 0.07 85.4 89.8 90.3
142 58.05 0.05 38.1 11.7 46.3
143 53.07 0.03 94.9 78.5 99.7
144 57.14 0.10 61.7 34.9 95.1
145 81.73 0.12 85.5 37.4 97.6
146 109.05 0.13 67.8 24.4 76.8
147 68.26 0.08 77.7 75.8 49.6
148 73.98 0.00 22.9 26.4 35.6
149 66.21 0.03 89.1 89.3 90.2
150 77.84 0.03 94.3 63.0 100.0
151 91.97 0.06 27.8 21.4 97.2
152 45.41 0.05 87.4 33.3 100.0
153 76.44 0.09 13.3 38.0 50.9
154 65.44 0.07 71.6 34.3 85.7
155 62.89 0.10 13.3 2.1 37.9
156 46.94 0.05 27.0 0.5 98.4
157 56.71 0.01 26.4 5.7 55.0
ARA-A 60.81 0.01 --- --- ---
CAMPTO 43.30 0.01 --- --- ---
DPM 82.78 0.02 97.4 98.2 79.5
% Inhibition
Table A.3.  Cytotoxicity, nucleoside transport inhibition, and antitumor promotion data 
for Group 3 DPM analogues. 
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Compound # % Viability  Std. Dev ENT1 Uptake ENT2 Uptake
Tumor 
Promotion
158 97.84 0.10 71.0 25.7 45.0
159 63.33 0.09 83.2 76.9 98.1
160 49.60 0.04 96.7 75.0 99.1
161 91.34 0.13 89.8 86.8 89.1
162 100.97 0.03 60.8 0.0 34.2
163 88.04 0.04 21.1 1.8 22.7
164 93.07 0.02 94.1 79.5 100.0
ARA-A 60.81 0.01 --- --- ---
CAMPTO 43.30 0.01 --- --- ---
DPM 82.78 0.02 97.4 98.2 79.5
% Inhibition
Table A.4.  Cytotoxicity, nucleoside transport inhibition, and antitumor promotion data 
for Group 4 DPM analogues. 
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APPENDIX B:  ANTITUMOR PROMOTION DOSE RESPONSE CURVES AND 
IC50 DATA FOR DPM AND ANALOGUES 
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Figure B.1.  Antitumor promotion dose response curves and IC50 data for DPM, 104, and 108. 
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Figure B.2.  Antitumor promotion dose response curves and IC50 data for 113, 115, and 121. 
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Figure B.3.  Antitumor promotion dose response curves and IC50 data for 137, 138, and 145. 
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Figure B.4.  Antitumor promotion dose response curves and IC50 data for 146, 149, and 151. 
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Figure B.5.  Antitumor promotion dose response curves and IC50 data for 161, and 164. 
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